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SUMMARY 
 
 
Context: Previous data of my research group showed a decreased expression of vitamin 
D receptor (VDR) mRNA/protein in a small group of adrenocortical carcinoma (ACC) 
tissues, suggesting the loss of a protective role of VDR against malignant cell growth in 
this type of cancer. Downregulation of VDR gene expression may result from epigenetics 
events, that is, methylation of cytosine nucleotide of CpG islands in VDR gene promoter.  
Objective: To analyse methylation of CpG sites in the VDR gene promoter in a series of 
ACC tissue specimens, comparing malignant adrenocortical tumour samples with those 
from various benign forms and normal adrenals. 
Methods: Methylation of CpG-rich 5′ regions was assessed by bisulfite sequencing PCR 
using bisulfite-treated DNA from archival microdissected paraffin-embedded 
adrenocortical tissues. Three normal adrenals and twenty-three various adrenocortical 
tumour samples including eight carcinomas and fifteen adenomas were studied.  
Results: Methylation in the promoter region of VDR gene was found in three of eight 
ACCs, while no VDR gene methylation was observed in normal adrenals and 
adrenocortical adenomas. VDR mRNA and protein levels were lower in ACCs than in 
benign tumours. VDR immunostaining was weak or negative in ACCs, including all three 
methylated tissue samples.  
Conclusion: The association between VDR gene promoter methylation and reduced 
VDR gene expression is not a rare event in ACC, suggesting that VDR epigenetic 
inactivation may have a role in adrenocortical carcinogenesis. Other epigenetic 
mechanisms in the upstream signalling pathway involved in silencing VDR gene 
expression in ACC should be investigated.  
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INTRODUCTION 
PART 1: ADRENOCORTICAL CARCINOMA 
1.1 EPIDEMIOLOGY 
Adrenal tumours are common, affecting 3% to 10% of the human population, and the 
majority are small benign non-functional adrenocortical adenomas (ACA). Conversely, 
adrenocortical carcinoma (ACC) is a very rare disease with an estimated incidence of 0.7-
2 cases per million population per year [1,2]. The US database Surveillance, 
Epidemiology, and End Results (SEER) reports an estimation of incidence of 
approximately 0.72 per million cases per year leading to 0.2% of all cancer deaths in the 
United States. The same database provides a mean age of 55 years [2]. The German ACC 
Registry reports a slightly younger median age at diagnosis of 46 years, and a large single 
centre series in France reported the same age [3]. Epidemiological data on ACC from 
larger cancer registries is sparse, as they are often grouped with other endocrine 
malignancies.  
A second peak of increased incidence affect childhood; approximately 1.3% of all 
childhood cancers are ACCs as opposed to 0.02% to 0.2% of adult cancers, confirming a 
higher relative incidence early in life [4-7]. In Southern Brazil the incidence during 
childhood ranges from 2.9 - 4.2 per million per year, and this is mainly dependent on the 
high prevalence of regional predisposing factors, particularly the p.R337H low 
penetrance germline mutation of TP53 [8,9].  
In the adult as well as in the paediatric population, there is a predilection for the female 
gender (ratio of female to male ranges from 1.5–2.5:1) [7,10]. A relative increase of 
diagnosis of ACC occurs during pregnancy [10,11].  
 
1.2 GENETIC PREDISPOSITION 
Most ACCs occur sporadically, but ACCs can also be associated with various genetic 
syndromes (Table 1), e.g. Li Fraumeni syndrome (LFS) [12], Beckwith–Wiedemann 
syndrome (BWS) [13], multiple endocrine neoplasia type 1 (MEN1) [14] and Lynch 
syndrome [15]. To a lesser extent, ACC can be associated with familial adenomatous 
polyposis (FAP) [16], neurofibromatosis type 1 [17], and Werner syndrome [18]. 
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Hereditary syndromes in patients with ACCs are summarised in Table 1. Aside from 
genetic predisposition, no risk factor have been firmly established.  
 
Table 1. Hereditary syndrome in patients with ACC [3]. 
Syndrome  Prevalence in ACC 
patients 
Prevalence 
in general 
population 
Gene 
mutation 
Phenotype 
LFS 3-7% of adults, 50-80% 
of children 
1:20 000 to  
1:1 000 000 
TP53 Sarcoma, choroid plexus tumour, 
brain cancer, early brest cancer, 
leukemia, lymphoma 
MEN1 1-2% of adults 1:30 000 MENIN Foregut neuroendocrine tumours, 
pituitary tumours, parathyroid 
hyperplasia, collagenoma, 
angiofibroma, adrenal 
adenoma/hyperplasia 
Lynch 
syndrome 
3% of adults 1:440 MSH2, 
MSH6, 
MLH1, 
PMS2 
Colorectal cancer, endometrial 
cancer, sebaceous neoplasms, 
ovarian cancer, brain cancer 
BWS Very rare, only children 1:13 000 IGF2, 
CDKN1C, 
H19 locus 
changes on 
11p15 
Wilm’s tumour, hepatoblastoma, 
macrosomia, adrenocortical 
cytomegaly, adreanle adenoma, 
adrenal cyst, hemihypertrophy, 
macroglossia, omphalocele, ear 
pits 
FAP Very rare (<1%) 1: 30 000 APC Intestinal polyps, colon cancer, 
duodenal carcinoma, thyroid 
cancer, desmoid tumour, adrenal 
adenoma, supernumerary teeth, 
congenital hypertrophy of the 
retina, osteoma, epidermoid cysts 
NF1 Very rare (<1%) 1: 3 000 NF1 Malignant peripheral nerve sheet 
tumour, pheocromocytoma, cafè 
au lait spots, neurofibroma, optic 
glioma, Lisch nodule, skeletal 
abnormalities 
Carney 
complex 
Very rare (case reports) ~700 cases 
worldwide 
PRKAR1A Primary pigmented nodular 
adrenal disease, large cell 
calcifying Sertoli cell tumours, 
thyroid adenoma, myxoma, 
somatotroph pituitary adenoma, 
lentigines 
  
The relative high incidence of ACC in childhood is mainly explained by germline TP53 
mutations, which are the underlying genetic cause of ACC in ~50% to 80% of children 
with ACC [19]. Childhood ACC is a core malignancy of LFS syndrome. Approximately 
3% to 10% of LFS-associated cancers are ACCs, suggesting that germline TP53 
mutations infer a significant contribution to increase risk of ACC development [20]. 
Prevalence TP53 mutations in ACC adult patients ranges between 3% and 7% [21]. TP53 
germline testing is recommended for any patient with a diagnosis of ACC [22], even when 
family history is lacking. Up to 25% of TP53 mutations occur de novo. Most of TP53 
mutation affect the DNA binding and tetramerization domains. One particular hot spot 
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mutation has been reported, the low penetrance tetramerization domain p.R337H in 
Southern Brazil [23], related to a funder effect in most cases.   
A hallmark of BWS is alteration of DNA methylation of the 11p15 locus, which harbours 
the coding regions for IGF2, the cell cycle regulator CDKN1C, and the non translated 
RNA H19. The result is an upregulation of IGF2 expression and a downregulation of 
other two transcripts. ACC comprises 5-15% of malignancies in BWS. Cancer risk of 
children with BWS decreases through adolescence and then remains at the level of the 
general population [13].  
A small fraction of patients with MEN1 will develop ACC, but in this setting adrenal 
lesions are very frequent and require special attention in order to recognise signs 
suggestive of ACC [14].       
Recently, a systematic analysis reported the prevalence of Lynch syndrome in patients 
with ACC to be near to 3%. All tested ACCs resulted microsatellite stable [15].  
Carney complex is a familial lentiginosis syndrome caused by PRKAR1A mutations and 
perturbations of the cyclic AMP-dependent protein kinase (PKA) signalling pathway. In 
addition to the cutaneous findings, the main tumours associated with Carney complex are 
endocrine. ACC has been reported in 2 cases of patients with Carney complex [24,25].   
The association between ACC and hereditary cancer syndromes led to the discovery of 
the role of several genes and signalling pathways involved in adrenocortical 
tumorigenesis, such as β-catenin signalling (FAP) and IGF-1 (BWS).  
 
 
1.3 CLINICAL PRESENTATION 
Clinical presentation of patients with ACC can be heterogeneous. Symptoms and signs of 
hormone excess are the major complaints in up to 60% of ACC patients. About a third of 
patients present with nonspecific symptoms, due to local tumour growth, such as 
abdominal or flank pain, abdominal fullness, or early satiety [10]. In the remaining cases 
(20% to 30%), ACCs are incidentally diagnosed by imaging procedures for unrelated 
medical issues. Paraneoplastic syndromes are uncommon, but hypoglycaemia could 
occur and is attributed to IGF-2; other rare paraneoplastic syndromes are hyperreninemic 
hyperaldosteronism, erythropoietin-associated polycythemia, and leucocytosis [26-28]. 
Generally, signs/symptoms of hormone excess are often not readily recognized by 
physicians, leading to delay in diagnosis and subsequent surgical and/or medical therapy. 
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Hypercortisolism is the most common presentation of patients presenting with hormone 
excess (50%–80% of hormone-secreting ACCs). Frequently, very high cortisol levels in 
ACC saturate the renal 11-Beta-Hydroxysteroid Dehydrogenase Type 2  (HSD11B2) 
system, resulting in glucocorticoid-mediated mineralocorticoid receptor activation. 
Therefore, hypokalemia and hypertension are commonly observed in ACC patients with 
hypercortisolism. The second most commonly produced hormones in patients with ACC 
are adrenal androgens (40%–60% of hormone-secreting ACCs), leading to hirsutism, 
virilisation, and menstrual irregularities in women. Concurrent androgen and cortisol 
production is not rare. Oestrogen production occurs in 1% to 3% of male ACC patients, 
causing gynecomastia and testicular atrophy.  Androgen or oestrogen overproduction 
should always raise the suspicion of a malignant tumour. Steroid precursors such as 11-
deoxycorticosterone could mimicry mineralocorticoid effects [29,30]. 
At the time of presentation, ACCs are generally large tumours, measuring on average 10 
to 13 cm [31,32]. A minority of tumours are < 6 cm (9%–14%), with only 3% presenting 
as lesions < 4 cm [31,33]. Contralateral metachronous or synchronous adrenal tumours 
can be found in ~5% of patients. The most common metastatic sites are lung (40%–80%), 
liver (40%–90%), and bone (5%–20%) [3].  
 
1.4 DIAGNOSTIC WORK-UP 
The initial evaluation should include patient history, family history to identify possible 
hereditary contribution, and physical examination with particular respect to symptoms 
and signs of hormone excess. Patients should undergo biochemical assessment with 
particular respect to hormonal workup. Staging should at the minimum include a 
computed tomography (CT) scan or magnetic resonance imaging (MRI) of the 
abdomen/pelvis and a CT of the chest. Other imaging should be guided by clinical 
suspicion.  
1.4.1 Biochemistry  
Measurement of steroid hormones produced by the tumour is the hallmark of biochemical 
evaluation in ACC. To note, biochemical exclusion of a pheochromocytoma by 
measuring levels of metanephrine and normetanephrine in plasma or 24-hour urine is 
mandatory, especially when no steroid hormone production is evident, in order to prevent 
unexpected complications during surgery or treatment.  
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Suppressed ACTH (≤10 pg/mL) and increased cortisol on a blood sample collected at 
8:00 AM are common features in patients with cortisol-secreting tumours. Diagnosis of 
hypercortisolism is usually established by a 1-mg dexamethasone suppression test (DST), 
midnight salivary cortisol, or elevated 24-hour urine free cortisol. Screening for 
aldosterone production includes measurement of plasma renin activity and serum 
aldosterone levels. Isolated suppression of renin without elevated levels of aldosterone is 
related to volume repletion, reflecting the mineralocorticoid activity of cortisol and/or 
steroid precursors. Dehydroepiandrosterone sulfate (DHEAS) and total or bioavailable 
testosterone should be measured in every patient. Measurement of other steroid 
metabolites, such as 17-hydroxyprogesterone (17-OH-progesterone), androstenedione, 
and oestrogen is generally recommended, allowing specific treatment with hormonal 
antagonists to alleviate symptoms [3].  
ENSAT suggested preoperative laboratory workup comprises assessment of basal 
cortisol, ACTH, DHEAS, 17-OH-progesterone, androstenedione, testosterone, and 
oestradiol as well as a dexamethasone suppression test and urinary free cortisol excretion. 
Aldosterone/renin ratio is measured in patients with hypertension or hypokalemia. 
Although the cost effectiveness of this approach is unproven,  this extensive panel appears 
useful for several reasons: it may prove the adrenocortical origin of the lesion, suggest 
malignancy, and document autonomous glucocorticoid excess that, if missed, regularly 
entails postoperative adrenal failure [1].  
Despite the presence of a large tumour, signs or symptoms of steroid hormone excess and 
blood levels of hormones in ACC can be absent or minimal. In fact, in comparison with 
the normal adrenal cortex, steroid hormone synthesis in ACC is relatively inefficient, 
resulting in elevated levels of a variety of steroid hormone precursors but only modestly 
elevated hormone levels, even in the presence of a large lesion. Although most of these 
metabolites are not routinely measured clinically, they can be detected by gas 
chromatography/mass spectrometry analysis [3].  Arl et coll. identified 11-deoxycortisol 
metabolite tetrahydro-11-deoxycortisol as the most discriminative marker, although 
integrated profile of several metabolites provided more information.  Routine use of the 
recently introduced urine steroid metabolomic analysis might further increase this number 
and may serve as a fingerprint of the tumour, facilitating early detection of recurrence 
[34].  
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1.4.2 Imaging 
Together with a careful endocrine workup, modern cross-sectional imaging is able to 
correctly diagnose an adrenal mass as ACC before surgery in most cases. ACCs are 
generally large tumours, often measuring more than 6 cm in diameter and frequently 
combining the presence of internal haemorrhage, necrosis, and calcification. Contrast-
enhanced computed tomography (CT) or magnetic resonance imaging (MRI) is the 
diagnostic imaging modality of choice for initial imaging and staging as well as for 
detecting local recurrence and metastatic disease [35]. Functional imaging by positron 
emission tomography (PET) with [18F]fluorodeoxyglucose (FDG) and [11C]Metomidate 
(MTO) or [123I]MTO (where available) may be used to confirm diagnosis of a malignant 
lesion or establish the adrenocortical origin of a tumour. [131I]-iodocholesterol scans are 
no longer available.  
CT and MRI 
On CT imaging, ACCs are large and heterogeneous masses and can be distinguished from 
lipid-rich ACAs, which tend to be small, homogeneous masses that measure ≤ 10 
Hounsfield Units (HU) on unenhanced CT. On state-of-the-art MRI, ACCs appear 
isointense to hypointense relative to liver parenchyma on T1-weighted images and 
hyperintense relative to liver parenchyma on T2-weighted images, and demonstrate loss 
of signal on chemical-shift MRI. In ACC, contrast-enhanced imaging often demonstrates 
heterogeneous, predominantly irregular peripheral enhancement with central non-
enhancing areas due to haemorrhage or necrosis. Internal hemorrhage is seen as ill-
defined areas of increased attenuation on non–contrast-enhanced CT and as areas of high 
signal intensity on T1-weighted images. Areas of necrosis have low attenuation on non–
contrast-enhanced CT, high signal intensity on T2-weighted images and do not enhance 
after administration of intravenous contrast [36]. Calcifications can be present in 
approximately 30% of cases and are best detected on CT imaging; calcification is not a 
distinguishing feature as it is also present in other adrenal pathologies such as 
myelolipoma and approximately 10% of pheochromocytomas. Due to the multiplanar 
capability of MRI, direct invasion of adjacent organs may be better depicted [3].  
[18F]FDG PET/CT imaging 
ACCs typically present intense FDG uptake greater than liver background. In a study of 
77 patients with surgically proven diagnosis of ACA or ACC, [18F]FDG PET/CT had a 
sensitivity of 100% and specificity of 88% in distinguishing benign from malignant 
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lesions by using cut-off value above 1.45 for adrenal to liver maximum standardized 
uptake value (SUV) [37]. In a meta-analysis of published data aimed at determining the 
diagnostic utility of [18F]FDG PET/CT for distinguishing benign from malignant adrenal 
tumours, [18F]FDG PET/CT had sensitivity of 97% and specificity of 91%. [18F]FDG 
PET/CT, however, is not a tumour-specific tracer and cannot distinguish ACC from other 
pathologies like metastases, lymphoma, or pheochromocytoma, which also have high 
metabolic activity [38]. [18F]FDG PET/CT can be an imaging modality complementary 
to CT for evaluating local recurrence or diagnosis of metastasis in selected cases, but 
sensitivity decreases for lesions less than 1 cm in diameter. A maximum SUV of >10 was 
found to be related to survival, indicating poor prognosis [39]. 
 
Experimental imaging modalities 
Proton MR spectroscopy may be helpful in differentiating ACAs and 
pheochromocytomas from ACC and metastases using choline to creatine ratios of greater 
than 1.2 (92% sensitivity and 96% specificity) and choline to lipid ratios greater than 0.38 
(92% sensitivity and 90% specificity) [35]. However, more research data and prospective 
clinical evaluation are needed to substantiate this approach. Metomidate is an inhibitor of 
11β-Hydroxylase (CYP11B1) and aldosterone synthetase (CYP11B2), [11C]Metomidate 
and [123I]Iodometomidate are highly specific tracers for PET-imaging of adrenocortical 
tissue but they cannot distinguish benign from malignant lesions [40].  
 
1.5 STAGING 
Consensus has been obtained during the last years that the tumour staging classification 
suggested by the European Network for the Study of Adrenal Tumors (ENSAT), reliably 
predicts the outcome of patients (Table 2) [41,42]. In this staging system, which is a 
modification of the Lee classification from 1995, stage I and stage II are defined as strictly 
localized tumours with a size of ≤ 5cm or > 5 cm, respectively. Stage III tumours are 
characterized by infiltration in surrounding tissue, positive regional lymph nodes, or a 
tumour thrombus in the vena cava/renal vein. Stage IV is restricted to patients with distant 
metastasis. Although this staging system can differentiate patient cohorts with different 
prognosis and a 5-year stage-dependent survival of 81, 61, 50, and 13% [42] (Figure 1), 
there is a need for further improvements; e.g., by adding a grading system [43]. Recently, 
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Asare et al. reported that predicting 5-year overall survival rates in patients with stage I/II 
ACC would improve if patient age is added to the ENSAT staging [44]. 
 
 
 
Table 2. ENSAT staging system for ACC. 
Tumours are classified as follows: T1, tumour 
≤5 cm; T2, tumour >5 cm; T3, tumour 
infiltration into surrounding (fat) tissue; T4, 
tumour invasion into adjacent organs or venous 
thrombus in vena cava or renal vein; N0, no 
spread into nearby lymph nodes; N1, positive 
lymph node(s); M0, no distant metastasis; M1, 
presence of distant metastasis [3]. 
Figure 1. Disease-specific survival stratified 
according to the European Network for the 
Study of Adrenal Tumors (ENSAT) staging 
classification for adrenocortical carcinoma 
(ACC) using Kaplan-Meier analysis. Disease-
specific survival was defined as the time elapsed 
from primary diagnosis to death from ACC. 
Patients who were alive or who had died of 
other causes were censored. Four hundred 
sixteen patients were analysed (stage I: n=23 
patients, 4 deaths, 19 censored; stage II: n=164 
patients, 48 deaths, 116 censored; stage III: 
n=107 patients, 52 deaths, 55 censored; stage 
IV: n=122 patients, 89 deaths, 33 censored). HR 
indicates estimated hazard ratio (with 95% 
confidence intervals are indicated in 
parentheses); P indicates log-rank P value 
assessing differences [31].  
   
 
1.6 PATHOLOGY 
The Weiss score is currently the most widely employed classification system for the 
pathological assessment of adrenocortical tumours [45]. It is based on the recognition at 
light microscopy of at least three among nine morphological parameters [46] that are 
focused on invasion by tumour into capsule and adjacent vessels, changes in growth 
patterns, presence of tumour necrosis, increased mitotic rates, and the presence of atypical 
mitotic figures. Tumours with an abundance of these features (score 3 or more according 
to the Weiss system) most often behave in a malignant fashion and can be classified as 
ACC, whereas tumours without these features (score 0–2 in the Weiss system) do not 
metastasize and can be classified as ACA. The Weiss scoring system is able to diagnose 
metastatic ACC with 100% sensitivity and 99.4% specificity. 
ENSAT Staging System for ACC 
 STAGE I T1, N0, M0 
STAGE II T2, N0, M0 
STAGE III 
T1-2, N1, M0 
T3-4, N0, M0 
STAGE IV T1-4, N0-1, M1 
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More simplified algorithms have been proposed because of the lack of reliability for some 
Weiss criteria (Table 3). This modified system, based on the most reliable criteria (2 x 
mitotic rate + 2 x cytoplasm + abnormal mitoses + necrosis + capsular invasion) has a 
significant correlation with the Weiss system (r = 0.98) [47]. The Helsinki score, 
developed by Pennanen et al., consists of the sum of 3 x mitotic rate + 5 x presence of 
necrosis + maximum proliferation index and it has been recently validated [48,49].  
Table 3. Original Weiss criteria and modified Weiss criteria 
Original Weiss criteria for malignancy [50] (requires 3+ of these factors): 
 Nuclear grade III or IV based on Fuhrman criteria 
 > 5 mitotic figures/50 HPF (40x objective), counting 10 random fields in area of greatest 
number of mitotic figures on 5 slides with greatest number of mitoses 
 Presence of atypical mitotic figures (abnormal distribution of chromosomes or excessive 
number of mitotic spindles) 
 Clear or vacuolated cells comprising 25% or less of tumour 
 Diffuse architecture (more than 1/3 of tumour forms patternless sheets of cells; trabecular, 
cord, columnar, alveolar or nesting pattern is not considered to be diffuse) 
 Microscopic necrosis 
 Venous invasion (veins must have smooth muscle in wall; tumour cell clusters or sheets 
forming polypoid projections into vessel lumen or polypoid tumour thrombi covered by 
endothelial layer) 
 Sinusoidal invasion (sinusoid is endothelial lined vessel in adrenal gland with little supportive 
tissue; consider only sinusoids within tumour) 
 Capsular invasion (nests or cords of tumour extending into or through capsule with a stromal 
reaction); either incomplete or complete 
 
Each criterion is scored 0 when absent and 1 when present in the tumour 
 
Modified Weiss criteria [47] (score of 3 or more suggests malignancy): 
 Mitotic rate > 5 per 50 high power fields 
 Cytoplasm (clear cells comprising 25% or less of the tumour) 
 Abnormal mitoses 
 Necrosis 
 Capsular invasion 
 Calculate: 2 x mitotic rate criterion + 2 x clear cytoplasm criterion + abnormal mitoses + 
necrosis + capsular invasion 
 
Each criterion is scored 0 when absent and 1 when present in the tumour 
 
 
The reliability of the Weiss score is challenged in borderline cases, where a Weiss score 
of 2 can be suggestive for ACC [51,52]. The Weiss score lacks reproducibility and is 
difficult to apply in paediatric ACCs and in ACC variants. The most common is the 
oncocytic variant because the predominant cell type in this variant is an oncocyte, a cell 
with abundant, granular cytoplasm related to accumulation of mitochondria and 
endoplasmic reticulum. To prevent overdiagnosis in oncocytic variants with the classic 
Weiss score, an alternative diagnostic system was proposed [53] and also validated to 
correctly predict malignancy in this ACC subtype [54]. Rare ACC variants are the myxoid 
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variety, due to the production of abundant extracellular myxoid substances, and the 
sarcomatoid variety (carcinosarcoma), both generally portending aggressive tumour 
behaviour [55]. 
Because of these diagnostically challenging cases, many pathologists have tried to 
develop ancillary techniques to refine the approach to these tumours. Volante et al. 
demonstrated that disruption of reticular networks, defined as the loss of continuity of 
reticular fibres or basal membrane network as highlighted by histochemical staining was 
present in all 92 ACCs included in their study. This observation is related to the altered 
growth pattern observed in ACCs and reflects one of the Weiss criteria (diffuse growth 
pattern greater than 25%). By adding at least one of the following three parameters – 
necrosis, high mitotic rate or vascular invasion – this reticulin algorithm identified 
malignancy with a sensitivity and specificity of 100% [56]. After a specific training, the 
interobserver reproducibility was 86% in a study aiming to validate the presence of 
reticulin fibre disruptive changes in a series of 178 adrenocortical tumours [57]. This 
simple approach is intriguing and awaits further validation, concerning cortical tumour 
variants like oncocytic and myxoid subtypes [55].  
In addition to histochemical approaches, adrenal pathologists developed 
immunohistochemical methods in order to separate benign from malignant tumours. Most 
of these studies focus on tumour cell proliferation [3]. Using accepted proliferation 
immunomarkers, such as Ki67, a general consensus has emerged that ACCs have a Ki67 
labelling index > 5%. Conversely, ACAs generally show a much lower index, although 
there is some overlap observed depending on the particular study. Ki67 evaluation seems 
to be reproducible, with intra- and inter-observer differences of 3.7 and 4.2% respectively 
[58]. Proliferation markers generally correlate with mitotic accounts and do have a role 
to play in the evaluation of these tumours. In a large study (n=319, validation cohort 
n=250; all patients after complete resection of the tumour) evaluating the prognostic value 
of histopathological, clinical and immunohistochemical markers, Ki67 alone most 
powerfully predicted recurrence-free and overall survival [59].  In addition, the Authors 
recommend that based on their results Ki67 should be introduced in the routine pathology 
for adrenocortical tumours. 
ACCs can be graded into low- and high-grade based on their mitotic rates (≤ 20 mitoses 
per 50 high-power fields [HPFs] vs >20 mitoses per 50 HPFs). ACCs exhibit a large 
degree of intra-tumour heterogeneity, an unsurprising finding given their large size and 
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the evolutionary nature of cancer progression. Tumours consisting of numerous areas 
with different histological phenotypes are not uncommon. Similarly, it is possible to find 
tumour nodules within a given mass with different immunohistochemical phenotypes. 
These observations provide support for a clonal model in which ACC can exhibit step-
wise progression from low to high-grade carcinoma [60].  
Most adrenocortical tumours are readily apparent on routine hematoxylin and eosin stains 
and do not require supplemental immunostains to document adrenocortical 
differentiation. In difficult cases, a battery of immunostains could provide evidence of 
adrenocortical differentiation, including but not limited to the following proteins that are 
expressed in most ACCs: α-inhibin, calretinin, synaptophysin, melanA (Mart1), and 
steroidogenic factor 1 (SF1). In general, ACC does not express the common cytokeratins 
most often used in practice. Chromogranin A expression is universally not present, and if 
it is present, an adrenomedullary tumour should be strongly considered [3].  
Primary or metastatic tumours of unknown origin would involve a larger panel of the 
adrenocortical and adrenomedullary markers as well as other non-adrenal markers. The 
most common tumours metastasizing to the adrenal gland are lung carcinoma, melanoma, 
renal cell carcinoma, and breast carcinoma. With the exception of renal cell carcinoma, 
these tumours generally possess a distinct morphology that will immediately suggest 
metastatic disease. Bilateral adrenal masses strongly suggest metastatic carcinoma or 
lymphoma.  
Much work is proceeding on how the molecular pathobiology of adrenocortical tumours 
can be translated into practical tools that will enhance the routine pathological evaluation 
of these tumours beyond standard histopathology, immunohistopathology, mitotic 
grading, and tumour staging.  
 
1.7 MOLECULAR PATHOLOGY 
Classical genetic tools (i.e., DNA content assessment, metaphase spreads, and 
comparative genomic hybridization [CGH]) and the advent of high resolution analytic 
methods (i.e., tiled arrays and whole genome sequencing) have revealed several genomic 
aberrations and molecular markers that are predicted to contribute to neoplastic 
transformation of adrenocortical cells. 
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1.7.1 DNA content 
Aneuploidy is a genomic aberration related to chromosomal instability consistently 
reported in most cancers. One of the first genetic study on ACC based on flow cytometry 
showed aneuploidy in 4 of 4 ACCs, yet only diploidy or tetraploidy in normal adrenal 
cortices and benign adrenal tumours [61]. The results were validated in other two studies, 
reporting aneuploidy in 5 of 6 ACCs [62] and in 6 of 8 ACC samples [63] respectively, 
the latter one revealing a high correlation with Weiss score > 3. No significant difference 
in overall survival was observed in patients with ACC exhibiting aneuploidy vs patients 
with ACC exhibiting diploid neoplasms. Further investigation is required in order to 
establish the role of aneuploidy and hyperploidy as etiological factors that drive 
tumorigenesis or as an epiphenomenon. 
 
1.7.2 Chromosomal aberrations 
Comparative genomic hybridization (CGH) can identify structural chromosomal 
abnormalities within ACCs at a higher resolution. A complex pattern of chromosomal 
alterations occurs in ACCs, while ACAs present few regions of chromosomal gains and 
losses [64], suggesting that genes critical for carcinogenesis, i.e. oncogenes and tumour 
suppressor genes, rely on regions of gains and losses respectively.  
In ACCs, chromosomal gains were frequently observed in regions 4q, 4p16, 5p15, 5q12–
13, 5q32-qter, 9q34, 12q13, 12q24, and 19p, and chromosomal losses were reported at 
1p, 2q, 11q 17p, 22p, and 22q. Interestingly, 9q34 contain the steroidogenic factor 1 (SF1) 
gene, supporting the hypothesis of its direct involvement in adrenocortical cell 
proliferation [65]. Microsatellite studies identified frequent allelic losses in regions 
17p13, 11q15, and 2p16 (85%, 92%, and 90% of samples, respectively) [66]. Gains in 
chromosome 5 and 12 with additional gains in chromosome 7 and 16 were identified in a 
series of adrenocortical tumours including both ACCs and ACAs. The same study 
reported multiple loci of high-level, multiple amplifications specifically at 19p13.3 and 
19q13.4 and revealed a positive correlation between the number of aberrations and the 
size of tumours [67].   
A recent study with higher-resolution CGH arrays in a large series encompassing 86 
ACAs and 52 ACCs confirmed increased alterations in ACCs (44%) compared with 
ACAs (10%). In ACCs, the frequently observed chromosomal gains at 5, 7, 12, 16, 19, 
and 20 and losses at 13 and 22. The group identified genes within these regions with 
potential tumorigenic potential including fibroblast growth factor 4 (FGF4), cyclin-
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dependent kinase 4 (CDK4), and cyclin E1 (CCNE1). Moreover, Barreau et al. also 
developed a diagnostic tool to identify malignancy of adrenal tumours with a sensitivity 
of 100% and a specificity of 83% by combining DNA copy number estimates at six loci 
(5q, 7p, 11p, 13q, 16q, and 22q). Cluster analysis based on gains and losses in DNA could 
also identify two groups of ACC with different survival rates [64].  
A separate CGH study identified a similar increase in copy number in chromosomes 5, 
6q, 7, 8q, 12, 16q, and 20 and allelic losses in 1, 2q, 3, 6p, 7p, 8p, 9, 10, 11, 13q, 14q, 
15q, 16, 17, 19q, and 22q. A subgroup of these alterations (gains in 6q, 7q, and 12q and 
losses in chromosomes 3, 8 10p, 16q, 17q, and 19q) resulted associated with decreased 
overall survival [3]. 
Partly in concordance with the previous reports, chromosomes 1, 5, 7, and 12 were 
selected to separate ACCs (n=22) from ACAs (n=24), which appeared more evident when 
considering only chromosome 5 [68]. More recently, frequent recurrent copy number 
variations were identified at 5p15 and deletions at 22q12.1 [69]. Regions contain TERT, 
encoding telomerase reverse transcriptase, and the ZNRF3 gene, which is recently 
reported to act as a tumour suppressor gene respectively. 
All together, these studies indicate genetic diversity and heterogeneity of chromosomal 
gains and losses in ACC. The utility of chromosomal aberrations in diagnosing 
malignancy of adrenocortical tumours remains to be fully elucidated. 
 
1.7.3. Differential gene expression 
Global gene expression studies aim to identify biomarkers that could provide diagnostic 
and prognostic utility in addition to the classic histological analyses. Furthermore, this 
approach hold the promise of new potential targets for ACC therapy.  
ACAs and ACCs show distinct gene expression profiles [70-72]. IGF2 is the most widely 
known overexpressed gene in ACCs, nevertheless IGF2 alone is not able to sufficiently 
distinguish ACCs from ACAs. Using microarray analysis, De Frapoint et al. identified 
two clusters of genes whose combined levels of expression could correctly discriminate 
ACCs from ACAs: 75% of ACCs expressed high levels of eight genes of the IGF2 cluster, 
whereas 93% of ACAs highly expressed fourteen genes representing the steroidogenic 
cluster [70]. Soon et al. reported a high diagnostic accuracy (96% sensitivity, 100% 
specificity) combining IGF2 and Ki67.  MAD2L1, CCNB1, ABLIM1, NAV3, SEPT4, and 
RPRM were identified differentially expressed in ACCs compared to ACAs [73]. Among 
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a group of 614 genes, TOP2A and IGF2, CCNB2, CDC2, CDC25C and CDKN1C were 
the most differentially expressed genes in the series analysed by Tombol et al. [74]. 
Recently, several Authors have correlated expression profiles in ACC with clinical 
outcome. Specifically, Giordano et al. [72] determined that ACCs with high histological 
grade exhibited marked overexpression of cell cycle and functional aneuploidy genes, 
which correlated with decreased overall survival. After reporting ALDH1A1, IGF2, USP4 
and UFD1L as the four most upregulated genes in ACCs compared with ACAs, Laurell 
et al. employed hierarchical clustering and identified two subclusters of patients with 
short survival (<9 months) and long survival (>67 months) [75]. 
Expression levels of BUB1B and PINK1 alone identified subgroups of paediatric ACCs 
with different overall survival, regardless of tumour stage. Similarly, the expression levels 
of DLG7 and PINK1 identified subgroups of ACCs with distinct disease-free survival, 
regardless of tumour grade [71]. These findings were later validated in a separate cohort 
of adult patients [76]. 
 
1.7.4 DNA methylation 
DNA methylation involves the addition of a methyl group to the cytosine pyrimidine ring 
or adenine purine ring, occurring typically at CpG dinucleotides. It acts as a regulatory 
mechanism for proper gene expression in normal cells. Aberrant methylation is a 
mechanism of altered gene expression often occurring in tumorigenesis [77]. To date, 
research has focused on candidate gene approaches as well as genome-wide methylation 
level analysis. 
Insights into the possible role of gene methylation in ACC tumorigenesis come from the 
observation of the association of ACC with the Beckwith-Wiedemann syndrome. Many 
of these subjects show abnormal DNA methylation in different areas of 11p15 
chromosomal region – containing IGF2, H19, and CDKN1C – meaning that normal 
epigenetic marks that regulate imprinted genes in this region are altered. As a result, 
overactivity of the IGF2 gene and/or no active copy of the antiproliferative gene 
CDKN1C occur. In sporadic ACC, DNA methylation of the H19 promoter has been 
shown to be correlated with H19 and IGF2 expression [78]. Very recently, Creemers et 
al. analysed methylation of regulatory regions of IGF2 using pyrosequencing, and they 
found that specific methylation patterns of these regions can discriminate ACCs from 
ACAs with high diagnostic accuracy [79]. In contrast to some other cancer types, TP53 
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methylation is not reported as a mechanism of tumour suppressor gene inactivation in 
ACC [80]. 
A genome-wide approach to study methylation status was first performed by Rechache et 
al. Global hypomethylation was found in primary (n=8) and metastatic (n=12) ACC 
samples compared to normal adrenals (n=19) and ACAs (n=48). Fifty-two genes were 
down-regulated and hypermethylated in primary adrenocortical tumour samples, 
suggesting methylation as a potential regulator of expression in ACC [81].  
Fonseca et al. analysed 27578 CpG sites in 6 normal adrenals, 27 ACAs and 15 ACCs. 
212 CpG islands in promoter regions of genes involved in cell cycle regulation, apoptosis, 
and transcriptional regulation, were significantly hypermethylated in ACCs compared to 
ACAs and normal adrenal tissues. Of six selected genes, mRNA expression levels were 
concordantly significantly reduced in ACCs compared to ACAs and normal adrenal tissue 
[82].  
Along with this finding, Barreau et al. also confirmed ACC-specific hypermethylation in 
promoter regions in a series of 51 ACCs and 84 ACAs, identifying H19, PLAGL1, G0S2, 
and NDRG2 as silenced genes. In addition, the same Authors also correlated the 
methylation levels with prognostic features in patients with ACC [83] (for details see the 
section ‘Prognostic factors and predictive markers’).  
 
1.7.5 MicroRNAs 
MicroRNAs (miRNAs) are evolutionarily conserved, non-coding, 18- to 25-nucleotide 
RNAs that are involved in post-transcriptional regulation of gene expression [84]. Mature 
miRNAs in association with the RNA induced silencing complex are loaded onto the 3′-
untranslated region of the targeted mRNA to inhibit translation or to cause degradation. 
Dysregulation of miRNAs, such as overexpression or deletion, plays an important role in 
various diseases, including cancer [85].  
Examination of 36 adrenocortical samples (10 normal tissues, 10 non-functional ACAs, 
9 cortisol-secreting adenomas, and 7 ACCs) revealed differential expression of 22 
miRNAs, with 14 miRNAs upregulated in ACCs. Preferentially expressed miRNAs in 
ACCs included miR-184, miR-210, and miR-503. Downregulated miRNAs included 
miR-214, miR-375, and miR-511. Levels of miR-184, miR-503, and miR-511 alone were 
able to distinguish benign from malignant adrenal tumours (specificity, 80%–97%; 
sensitivity, 100%) [74]. 
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Similarly, in a series of 55 adrenal samples (6 normal tissues, 22 ACAs, and 27 ACCs) 
Soon et al identified 14 upregulated miRNAs and 9 downregulated miRNAs unique to 
ACC [86]. MiR-483-5p and miR-483-3p are the most overexpressed miRNAs in ACCs 
compared to ACAs, whereas miR-195 is often found underexpressed, comparably with 
other reports [87-89]. MiR-483, which is located in an intron of IGF2, was found to be 
significantly upregulated in paediatric ACCs, although a majority of the differentially 
expressed miRNAs were downregulated in ACCs, particularly miR-99a and miR-100, 
both involved in IGF1 signalling pathway [90]. 
Combinations of several miRNAs (miR-483-5p, miR-195, miR-503, miR-511, miR-335, 
miR-675, miR-139-3p) have been proposed as a tool for identifying malignancy of 
adrenal tumours [74,87]. Moreover, overexpression of miRNA-processing enzymes, 
particularly TARBP2, strongly discriminated carcinomas from adenomas [91] but data 
still need a validation for clinical use.   
 
1.7.6 Gene mutations 
Targeted genetic analyses, such as sequencing and single-strand confirmation analyses 
have identified somatic genetic changes in TP53, MEN1, IGF2, IGF2R, and CDKN2A 
(p16/INK4A).  
The association of TP53 gene mutations with ACC has been discovered in the setting of 
the Li–Fraumeni syndrome. TP53 located on 17p13 is the most commonly mutated gene 
in ACC, present in at least one third of ACCs [92], but other more recent studies reported 
frequencies of TP53 mutations ranging from 15 to 19.5% in ACC [69,93,94]. Prevalence 
of TP53 mutations is higher in paediatric ACC [55]. 
The second most frequently mutated driver gene in ACC is CTNNB1 (β-catenin). 
Mutations in CTNNB1 lead to activation of the WNT signalling pathway and these 
mutations have been shown to be a common event in both ACCs and ACAs, varying from 
20 to 30% of samples [95]. Upregulation of β-catenin in adrenocortical tumours was also 
confirmed with immunohistochemistry [96]. More recently, the high frequency of 
CTNNB1 mutations in ACC was confirmed by several studies, which reported somatic 
mutation frequencies of 10–16% [69,93,94]. Notably, TP53 and CTNNB1 mutations are 
mutually exclusive.  
Recently, Assié et al. identified ZNRF3 as a new tumour suppressor gene driving ACC 
pathogenesis, with inactivation of ZNRF in 21% of ACCs. The frequency of ZNRF3 
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mutations was even higher than TP53 mutations (16%). Inactivation was caused by a 
homozygous deletion in 75% of the mutated cases, whereas the other 25% were caused 
by missense and nonsense mutations [94]. In addition, mutations in ZNRF3 and CTNNB1 
appeared to be mutually exclusive. A second recent study confirmed this mutually 
exclusive behavior, although the frequency of ZNRF3 mutations was lower (10%) 
compared to the former study [69].  
Other genes frequently mutated in ACC include ATM (~13%), CDKN2A (~11%), RB1 
(~4 to 7%), MEN1 (~7%), KREMEN1 (~7%), DAXX (~6%), TERT (~6%), MED12 (~5%) 
and JAK3 (~4%), which almost always co-occurs with mutations in TP53, CTNNB1, or 
ZNRF3 [69,93,94,97]. Three additional studies screened for EGFR mutations in ACC and 
reported different frequencies, i.e. 0, 11 and 0% [55]. Four studies have screened ACCs 
simultaneously for mutations and copy number alterations using (targeted) next 
generation sequencing and CGH. In the first study, in which a large number of structural 
DNA changes in ACC was analysed, TP53 was found to be mutated in 15% of cases, 
ATM in 12.5% of cases and CTNNB1 in 10% [93]. Most frequent copy number alterations 
were amplification of the CDK4 gene, and deletion of the CDKN2A and CDKN2B genes. 
Interestingly, these genes are known actors of the RB/E2F pathway. Overall, 19/40 ACCs 
(47.5%) had at least one molecular abnormality. In a second study, Ross et al. performed 
a comprehensive genomic profiling of 29 ACC samples and found at least one alteration 
(a mutation, amplification, deletion, or truncation) in 22 cases (76%). Genomic alterations 
in NF1 (14%), CDKN2A (14%), ATM (10%), CCND2 (7%), CDK4 (7%) and DNMT3A 
(7%) were considered as the most common and potentially clinically relevant at the same 
time [98]. The third study showed, considering the different omics classifications, a 
strong correlation between clustering of patients with different prognosis based on 
transcriptome clusters, DNA methylation and miRNA expression [94]. The fourth study 
investigated recurrent copy number variations using the coverage of paired exome 
sequencing results (patient’s tumour vs normal), and reported somatic amplification of 
the TERT gene and deletion of ZNRF3 and KREMEN1 genes [69]. Based on two recent 
studies that used different genomic approaches, it is possible to conclude that the WNT 
signalling pathway is most frequently altered in ACCs [69,94]. Because of the lack of a 
discriminative value and the relative rarity of genetic abnormalities in ACCs, mutation 
studies are not primarily used to diagnose ACCs, but specifically to identify potential 
novel targets for therapy. 
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1.8 PATHOPHYSIOLOGY OF CELLULAR SIGNALLING PATHWAYS 
At least three cellular signalling pathways appear to be relevant for adrenocortical 
carcinogenesis and for identification of novel potential therapeutic targets.  
 
1.8.1 IGF-mTOR pathway 
The IGF signalling pathway consists of ligands (IGF1 and IGF2), receptors (IGF1 
receptor [IGF1-R], IGF2-R, and insulin receptor), IGF binding proteins 1–6, and IGF 
binding protein proteases. The binding of the mitogenic polypeptides to their receptors 
activates the downstream AKT/PI3K and MAPK pathways to regulate cellular processes 
of metabolism, differentiation, proliferation, and apoptosis. The IGF pathway regulates 
adrenal growth and maintenance, and steroidogenesis [3,99] (Figure 2).  
 
Figure 2. Scheme of growth factor pathways and potential therapeutic targets for ACC [100]. 
The findings of high IGF2 expression levels and the knowledge of an increased incidence 
of ACC in BWS led to the investigation of IGF-1R as a therapeutic target. In an NCI-
H295 xenograft mouse model, IGF pathway inhibition by the small-molecule inhibitor 
NVP-AEW541 and the monoclonal IGF-1R antibody IMCA12 showed an antitumor 
effect. Furthermore, the combined treatment of NCI-H295 cells with IGF-1R antagonists 
and mitotane resulted in a synergistic antiproliferative effect in vitro and in vivo in tumour 
xenografts [101,102].  
Linsitinib (OSI-906) was the first IGF1 blocker that reached a phase III trial, but 
unfortunately did not show an increased overall survival compared to placebo [103]. 
Various clinical studies targeting IGF signalling showed disappointing results. A 
potential explanation can be found in compensatory activation of other growth promoting 
pathways. Combination therapy with other targeting drugs could be considered. 
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Interestingly, Sirianni et al. highlighted a critical role for estrogen receptor (ER)-α in 17β-
estradiol and IGF2-dependent ACC proliferation, providing a rationale for targeting ERα 
to control ACC growth [104].  In addition, the same research group investigated estrogen-
related receptor (ERR)-α, a downstream nuclear effector of multiple pathways, as 
possible target for innovative treatment modalities in ACC [105].  
The role of the mammalian target of rapamycin (mTOR), a downstream effector of IGF2, 
has been investigated in adrenal tumours by several studies, and mTOR appeared to be a 
potential therapeutic target in a subset of patients with ACC [106]. Targeting mTOR 
signalling by everolimus caused tumour cell growth reduction in vitro and in mouse 
xenografts [107]. Preclinical studies support the idea that mTOR inhibitors can upregulate 
AKT phosphorylation in tumour tissue. To address and circumvent the problem of 
induction of upstream receptor tyrosine kinase signalling, Doghman & Lalli showed that 
a PI3K/mTOR dual inhibitor (NVP-BEZ235) significantly inhibited ACC cell 
proliferation. Phosphatidylinositol 3-kinase (PI3K) is a downstream signalling pathway. 
NVPBEZ235 antagonized rebound AKT activation, but induced ERK phosphorylation. 
In this light, the ERK inhibitor FR180204 in combination with NVP-BEZ235, 
synergistically inhibited ACC cell proliferation [108]. On the other hand, IGFs can 
activate escape mechanisms from mTOR inhibitors by stimulation of AKT or ERK 
activation [106]. This finding demonstrates the potential benefit and rationale for 
combination of an IGF1R antagonist with an mTOR inhibitor. De Martino et al. showed 
the effect of the mTOR inhibitor sirolimus on basal and IGF2 stimulated ACC cells in 
vitro. Sirolimus inhibited basal, as well as IGF2-induced, colony formation and colony 
size of ACC cells [109]. In a phase II study, the combination of cixutumumab, a fully 
human IGF1 monoclonal antibody directed at IGF1R, with temsirolimus, an mTOR 
inhibitor, was well tolerated and resulted in prolonged (6–21 months) stable disease in 
42% of the 26 patients with metastatic ACC [110]. 
 
1.8.2 WNT signalling pathway 
In the normal adrenal gland, the WNT/β-catenin signalling pathway plays a crucial role 
in both embryonic development and maintenance of the adrenal cortex. Recent 
examinations of adrenocortical tumours suggest that the WNT/β-catenin signalling 
pathway plays an important role in sporadic adrenocortical tumorigenesis.  
The pathway is differentiated into 3 diverging signalling cascades dependent on signal 
conduction through β-catenin (canonical pathway), ras homolog gene family small 
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GTPase (planar cell polarity pathway), or phospholipase C (WNT/calcium pathway). β-
catenin is normally sequestered in a destruction complex with adenomatous polyposis 
coli (APC), glycogen synthase kinase 3, and axin. In the canonical pathway, binding of 
the WNT ligand to its respective frizzled receptors results in release of β-catenin from the 
complex and translocation to the nucleus where it serves as a transcriptional cofactor [3]. 
Immunohistochemical analysis of 39 adrenal tumours revealed accumulation of β-catenin 
in 10 of 26 ACAs and in 11 of 13 ACCs, consistent with stabilized and hence activated  
β-catenin. Mutational analysis of the β-catenin gene CTNNB1 identified activating point 
mutations in both ACAs and ACCs [96,111]. The fact that both nuclear β-catenin 
accumulation and activating CTNNB1 mutations are present in ACAs as well as in ACCs 
suggests that WNT activation may be an early step in adrenocortical tumorigenesis, which 
precedes malignant transformation.  
The most widely investigated WNT inhibitor is CWP232291, which is in a Phase I trial 
for refractory acute myeloid leukemia (AML) (NCT01398462). CWP232291 can 
promote β-catenin degradation. The first results of effectiveness of targeting the WNT 
signalling pathway in ACC comes from in vitro inhibition of ACC cell proliferation by 
the small-molecule inhibitor PKF115-584 [112]. Gaujoux et al. showed that β-catenin 
silencing caused decreased cell proliferation, alterations in the cell cycle and increased 
apoptosis in adrenocortical cancer cells in vitro [113]. Clinical trials with WNT inhibitors 
in ACC have not yet been performed. 
 
1.8.3 Vascular endothelial growth factor 
Sustained angiogenesis is a hallmark of virtually all types of cancer and the vascular 
endothelial growth factor (VEGF) is a chief regulator of cancer angiogenesis. Elevated 
VEGF levels were identified in blood samples from ACC patients, and overexpression of 
VEGF receptor has been shown in ACC samples [55].  
An earlier clinical trial using bevacizumab, an anti-VEGF monoclonal antibody, proved 
to be ineffective [114]. Several studies have been undertaken with VEGF receptor 
inhibitors in patients with ACC. Three phase II studies evaluated sorafenib in 
combination with paclitaxel, sunitinib or axitinib respectively [115-117]. Sorafenib did 
not show an anti-tumour effect in patients, whereas sunitinib and axitinib showed a partial 
response in 14 and 62% of the patients respectively. 
The lack of efficacy of tyrosine kinase inhibitors monotherapy might depend on 
compensatory hyperactivation of other signalling pathways. In two ACC cell lines, Lin et 
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al. confirmed the activation of multiple tyrosine kinases during treatment with sunitinib, 
with ERK as the most activated tyrosine kinase [118]. An additive antiproliferative effect 
was observed when sunitinib was given in combination with an ERK inhibitor. 
Furthermore, induction of CYP3A4 by mitotane treatment may enhance drug metabolism, 
limiting the therapeutic efficacy of tyrosine kinase inhibitors [119].  
 
 
1.9 THERAPY 
Briefly, complete surgical resection (‘R0’) is currently the gold standard treatment for 
non-metastatic ACC or following local recurrence. Mitotane is the only FDA-approved 
drug for locally advanced inoperable and metastatic disease displaying single-agent 
activity of 10–30% tumour response rates based on its adrenolytic action, although with 
a high toxicity profile [3]. The only prospective phase III randomised clinical trial, FIRM-
ACT, showed that in advanced ACCs mitotane combined with etoposide, doxorubicin 
and cisplatin (EDP-M) provided some additional clinical benefit compared to mitotane 
plus streptozocin alone, but was associated with more serious adverse events [120]. A 
further prospective study evaluating mitotane vs. placebo in high-risk for recurrence 
patients, ADIUVO (https://clinicaltrials.gov/ct2/show/study/NCT00777244), is currently 
under way [121].  
 
 
1.9.1 Surgery 
Surgery is the treatment of choice for non-metastatic ACC. Complete R0 resection of 
ACC is currently the keystone and the only curative treatment option for patients with 
ACC. An operative planning by a surgeon experienced in the resection of malignant 
adrenal tumours is highly recommended in order to assure long-term local control of 
malignancy. Requiring ACC specialised knowledge of surgical technique and 
management strategies, adrenalectomies for suspected ACC should be performed only in 
specialised centres performing at least 20 adrenalectomies per year [122]. Poor initial 
surgical treatment can rarely be corrected, whether by reoperation, radiotherapy, or 
chemotherapy. When imaging characteristics could not exclude malignancy clearly, 
surgeons are obligated to approach the resection as a cancer operation. Failure to do so 
often leads to dismal outcomes. Despite accurate preoperative diagnostics, approximately 
25% of stage III cases are initially suspected to be stage II ACC but ultimately found to 
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have microscopic extension through the adrenal capsule. These cases highlight the 
importance of careful surgical technique including resection of all surrounding soft tissue 
and adjacent organs if necessary [3].  
Preoperative considerations include management and optimization of those patients with 
hormone excess, especially those with Cushing’s syndrome because of the numerous 
deleterious effects due to elevated cortisol, such as poor wound healing, infection, and 
metabolic derangements. Debulking for control of hormone excess in the setting of 
known metastatic disease is also performed in some situations. The long-term durability 
of hormone control is usually limited by the metastatic disease progression. The benefits 
of debulking must outweigh the risks of surgery, so that preoperative evaluation should 
include estimation of recovery periods and postoperative quality of life with respect to 
life expectancy. 
Resection of the primary tumour in stage IV disease needs to be individually addressed. 
In general, those with widespread distant metastatic disease in multiple organs or those 
with multiple metastatic deposits in one organ system unable to be completely resected 
should not undergo adrenalectomy. However, surgical treatment could be considered in 
selected cases, i.e. tumour burden remains stable or decreases after chemotherapy and/or 
mitotane and/or palliative radiation [120].  
Careful attention should be paid to the adrenal and renal veins, the inferior vena cava, and 
the aorta, including the take-off of the celiac and superior mesenteric arteries. 
Adrenalectomy in the setting of tumour thrombus within the vena cava (if the tumour is 
otherwise technically resectable) is reasonable. Obstruction or occlusion of the vena cava 
by tumour thrombus can lead to significant lower body and gastrointestinal tract oedema, 
which leads to significant patient suffering. Lack of resection in the setting of vena cava 
thrombus can quickly lead to death. If tumour resection is not technically feasible for 
other reasons, vena cava stents can be placed, leading to temporary prevention of 
occlusion [3].  
 
 
Lymph node dissection 
The role of lymph node sampling or formal regional lymph node dissection in the 
treatment of ACC remains unknown, and consensus within the field is needed . There is 
also no formal agreement on the extent of lymph node dissection. The main lymphatic 
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areas are the renal hilum and the origin of the celiac and mesenteric artery. Because lymph 
nodes ideally should be removed as part of the ‘en bloc’ resection, surgeons need to 
individually balance the increased risk due to extended surgery (e.g., bleeding) with the 
presumed benefit of radical lymph node dissection. The impact of regional lymph node 
metastasis upon overall survival provides impetus for earlier or more aggressive use of 
additional therapies when disease is present in the lymphatic system [123].  
 
Open vs laparoscopic surgery 
Controversy surrounds the appropriateness of laparoscopic adrenalectomy (LA) for 
patients with ACC, since a complete margin-negative tumour resection at the initial 
operation is critical. Published data comparing the efficacy of LA vs open adrenalectomy 
(OA) for ACC are limited. All large series are retrospective, include fewer than 200 
patients (with most reports including fewer than 10 patients), provide limited or no 
follow-up, are hampered by referral bias, and include patients who did not undergo their 
initial surgical resection at the referral centre. Recent recommendations by the American 
Association of Clinical Endocrinologists and the American Association of Endocrine 
Surgeons advocate OA by an experienced surgeon as the procedure of choice [124]. 
Conversely, the European Society of Endocrine Surgeons and European Society for 
Medical Oncology suggest LA could be performed for stage 1 and 2 ACC tumours less 
than 8 or 10 cm if an R0 resection is performed and surrounding peri-adrenal tissue 
removed [125]. However, it remains undetermined how to differentiate stage I and II 
ACCs from microscopic or unappreciated stage III ACC definitely before surgery. To 
date, existing data are inconclusive and more studies are needed to better judge the 
equivalence of LA to OA. 
 
Surgery for recurrent disease 
In the setting of recurrence, surgery is indicated in those patients with disease confined 
to one site or organ. Beyond that, decisions regarding resection must be carefully 
individualised. Disease recurrence in the peritoneum outside the tumour bed has the worst 
survival. Tumour grade influences the decision for reoperation because it correlates with 
survival. In patients with low-grade tumours, time of disease progression can be slower 
and lead to longer survival with resection of sites of recurrence or metastasis. In contrast, 
those patients with high-grade tumours benefit less from reresection, because other sites 
of disease often appear quickly [3]. 
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1.9.2 Adjuvant therapy 
Despite complete surgical tumour excision, patients with ACC remain at high risk for 
recurrence, typically ranging from at least 19% to 34% [3]. There is no doubt that an 
effective adjuvant treatment would be of great benefit [1]. Treatment modalities currently 
considered include mitotane, irradiation of the tumour bed, cytotoxic agents, or 
combinations of them.  
 
1.9.2.1 Mitotane 
Mitotane is a synthetic derivative of the insecticide dichlorodiphenyltrichloroethane 
whose adrenolytic activity was first described in dogs in 1948. In 1960 Bergenstal et al. 
reported responses to therapy with the isolated 1-(ochlorophenyl)-1-(p-chlorophenyl)-
2,2-dichloroethane isomer (o,p′DDD, mitotane) that harbors the adrenolytic activity [3]. 
Since then, further modifications and isolations of enantiomers have aimed to improve 
the adrenolytic activity, improve pharmacokinetics and reduce side effects, but 
unfortunately only marginal improvement occurred. To date, mitotane remains the only 
drug approved by the U.S. Food and Drug Administration and European Medicine 
Executive Agency for treatment of ACC [5]. 
 
Figure 3. Mitotane chemical structure (up) and transformation to the active metabolite (down) [126]. 
The pharmacological mechanism by which mitotane exerts its adrenolytic effect is still 
not completely understood. Mitotane leads with relative specificity to a destruction of the 
inner zones of the adrenal cortex, the zona fasciculata, and zona reticularis. The 
specificity of mitotane towards adrenal cortex may derive from metabolic transformation 
of the drug to an active product via an enzyme system that is unique to this tissue (Figure 
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3). Active metabolites produced by adrenal mitochondria, in turn, covalently bind to 
mitochondrial proteins hypothesized to inhibit mitochondrial respiration [126]. 
Furthermore, mitotane metabolites inhibit several enzymes in the adrenocortical 
steroidogenesis pathway, mainly at the level of the cholesterol side-chain cleavage 
enzymes CYP11A1 (which appears to be one of the covalently bound mitotane targets) 
and CYP11B1.  
Approximately 40% of mitotane is absorbed from the gastrointestinal tract, and a 
significant amount is distributed to fatty tissues. After a usual daily dose of 5 to 15 g/d, 
plasma levels range between 0 and 90 mg/L. Doses greater than 20 g regularly result in 
neurological side effects, which are reversible with normalization of plasma levels [3].  
 
Mitotane for adjuvant therapy 
Adjuvant treatment is routinely started as early as possible after surgery, generally within 
3 months. Previous studies showed a large variation in responses, however all were 
retrospective, with older studies lacking the advantage of cross-sectional imaging. 
In a recent large retrospective study, adjuvant mitotane therapy showed significant 
improvement in median tumour-free survival in patients with completely resected ACCs 
(42 vs 10 and 25 months in 2 control groups). Median overall survival was significant 
only in comparison with one of the control groups (110 vs 52 and 67 months) [121]. It 
seems that only a subgroup of patients may benefit, and primarily those with cortisol-
producing tumours, but results are inconclusive. These limitations have led to the 
currently only prospective randomized multicentre study for mitotane as an adjuvant 
therapy for low to moderate risk for recurrence ACC (ADIUVO). 
Although often usual practice, no study has formally evaluated the combination of 
mitotane and radiation therapy. This approach is supported by in vitro findings of 
mitotane acting as a radiation sensitizer [3]. 
 
 
Mitotane for recurrent and advanced disease 
The efficacy of mitotane therapy in the setting of not completely resectable, metastasized, 
or recurrent ACC is well established. Overall, 30% of patients show stable disease or 
partial remission after treatment with mitotane, but possibly confounding interpretation 
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of these results comes from a subgroup of patients that shows a very slow disease 
progression [3]. 
The most important prognostic factor is the mitotane plasma level. Most studies, 
including a large retrospective analysis, have defined the therapeutic mitotane level to be 
14 to 20 mg/L [127,128]. Only very few studies have analyzed patient-, tumor-, or drug-
related factors that may influence patient outcome and predict patients who may respond 
to mitotane therapy.  On the molecular level, RRM1 expression has been found to be 
inversely correlated with mitotane response. Low RRM1 expression was a predictor of 
response to mitotane therapy with prolonged tumour-free survival [129]. 
 
Mitotane management.  
Managing mitotane therapy is an intensive process and requires experience. The dose is 
initiated at 1 g twice daily and increased every 4 to 7 days by 0.5 to 1 g/d until a daily 
dose of 5 to 7 g is reached. A low-dose loading protocol has also been described, probably 
leading to fewer side effects, but the same efficacy, and increased patient compliance. 
Regardless of the initial protocol, appropriate monitoring of blood levels is key and 
readily available in most countries. After the initial loading phase, the mitotane dose is 
titrated to a blood level of 14 to 20 mg/L. Side effects are mainly gastrointestinal, 
neurological, and metabolic/endocrinological.  
Nausea and diarrhoea are most commonly dependent on the actual dose in contact with 
lumen of the gastrointestinal tract. These effects are rarely dose limiting and can be 
attenuated by distributing the mitotane amount into 3 or 4 daily doses. Gastrointestinal 
side effects are also often ameliorated by taking mitotane with food, specifically lipid-
rich foods. Mild to moderate side effects can also be treated with antiemetic and 
antidiarrheal medications. Patients should be carefully evaluated whether gastrointestinal 
symptoms could be due to adrenal insufficiency, in which case a hydrocortisone increase 
may ameliorate symptoms.  
Neurological side effects have a wide range from minor mental slowing, ataxia, and 
dysphasia to severe somnolence and lethargy. Neurological side effects are dependent on 
plasma mitotane levels and usually do not occur until blood levels rise higher than 20 
mg/L. Neurological side effects are the main limiting side effect.  
Mitotane therapy almost invariably leads to an increase in liver enzymes and 
hypercholesterolemia. Alkaline phosphatase and γ-glutamyl transferase (GGT) can 
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increase significantly, usually without clinical significance, but aspartate 
aminotransferase (AST) and alanine aminotransferase (ALT) show only mild elevation. 
When rapidly rising levels of AST and ALT or levels greater than 3-fold the normal range, 
mitotane therapy should be withheld and evaluation for mitotane-induced hepatotoxicity 
or other liver pathologies initiated. Hypercholesterolemia is best treated with a statin, 
preferably using a compound not metabolized by CYP3A4 [3].  
Major endocrine abnormalities result from the effect of mitotane on steroid hormone 
biosynthesis. Three main mechanisms lead to adrenal insufficiency and decreased 
bioavailability of cortisol: 1) inhibition of steroid hormone biosynthesis at the level of 
CYP11B1 and CYP11A1; 2) induction of CYP3A4 and increased 6β-hydroxylation of 
cortisol; and 3) induction of cortisol binding globulin (CBG). Adrenal insufficiency 
occurs invariably and is treated pre-emptively. All patients are started on a minimum of 
30- to 40-mg daily dose of hydrocortisone. Supraphysiological hydrocortisone doses up 
to 50 to 100 mg daily may be necessary because of the increased cortisol catabolism [3].  
Hydrocortisone therapy needs to be continued after cessation of mitotane until the patient 
does not show any clinical or biochemical evidence of adrenal insufficiency. Even after 
discontinuation of mitotane therapy, CYP3A4 induction and mitotane levels persist up to 
several months. Occasionally, mitotane may affect mineralocorticoid synthesis and 
replacement therapy with fludrocortisone therapy may become necessary.  
Other common endocrine side effects during mitotane treatment include hypogonadism 
in male patients, which often requires replacement therapy, and hypothyroidism [1].  
Several drugs regularly used in combination with mitotane, such as platinum-based 
cytotoxic drugs, doxorubicin, and etoposide are also metabolized by CYP3A4, potentially 
reducing their antineoplastic effect. This is especially important when evaluating new 
drugs and targeted agents. A study using sunitinib, which is metabolized by CYP3A4, 
raised concerns that several of the study subjects did not reach therapeutic levels of this 
drug [116].  
 
 
1.9.2.2 Cytotoxic chemotherapy 
Cytotoxic chemotherapy is currently a mainstay of treatment for advanced and 
metastasized ACC. The overall response to chemotherapeutic regimens is 30% and 50%, 
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when counting stable disease as a response. However, the response is invariably transient 
and short-lived (6–18 months).  
To establish a gold standard of cytotoxic chemotherapy for ACC, a recent phase 3 trial 
(FIRM-ACT, First International Randomized Trial in Locally Advanced and Metastatic 
Adrenocortical Carcinoma Treatment) compared the most promising regimens 
(etoposide, doxorubicin, cisplatin, mitotane [EDPM] vs streptozotocin, mitotane). This 
study confirmed the efficacy of chemotherapy and proved the superiority of EDPM [120]. 
The response rate was 20% and 50%, when stable disease was included. However, the 
median progression free survival, was short with a median of 5 months. Because of 
CYP3A4 induction potentially affecting cisplatin metabolism, there is criticism regarding 
whether chemotherapy without mitotane may be more successful .   
 
1.9.2.3 Targeted therapy 
The unfavourable prognosis of ACC using traditional therapies has led to the exploration 
of targeted agents, compounds with defined molecular targets, such as receptors or 
intracellular enzymes.  
The most data for targeted therapy exist for the IGF-1R antagonists. Several studies 
investigated drugs targeting IGF-1R in patients with stage 4 disease. The first studies 
investigated figtilimumab and IMCA12 (cixutumab) but results have been disappointing 
[55]. The phase 3 trial GALACCTIC investigated OSI906 (Linsitinib), a small-molecule 
inhibitor of IGF-1R and insulin receptor. Despite failing to show an effect on OS and PFS 
in the overall population, the promising responses seen in individual patients suggest the 
therapeutic potential of inhibiting IGF-1R in selected ACC cases [130]. 
A study using the multikinase inhibitor sunitinib showed stable disease in 5 of 35 patients. 
Concomitant mitotane treatment negatively affected patient response [116].  
Trials with new targeted drugs are under way, and altered regimens and combination 
therapies may hold some promise.  
 
Therapy for hormone excess 
In 40–60% of patients with ACC, the main complaints are due to hormone overproduction 
[31]. Treatment of these elevated hormone levels is mandatory. By different mechanisms, 
mitotane treatment can already result in control of hormone levels to some extent. Adrenal 
steroidogenesis inhibitors like ketoconazole or metyrapone (alone or in combination) can 
also be used, or more rarely aminoglutethimide or etomidate [55]. Mifepristone, a 
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glucocorticoid receptor antagonist, is another treatment modality against cortisol excess. 
To control androgen effects in women with androgen-secreting tumours and 
mineralocorticoid effects in patients with mineralocorticoid-secreting tumours, 
spironolactone can be administered [3]. Monitoring of the patient parameters is important 
in all cases, considering the risk on adrenal insufficiency. 
 
Radiation therapy 
Although traditionally considered ineffective for ACC, radiotherapy has been shown in 
several recent series to offer a significant improvement in disease control in both the 
adjuvant and palliative settings, although such an improvement has not been universally 
demonstrated [3]. Apart from the adjuvant setting, radiotherapy can be indicated: i) when 
microscopic tumour residues are visible after surgery; ii) when patients are not suitable 
for surgery (in this case radiotherapy is often in combination with mitotane); and iii) for 
palliative care. Several studies have shown efficacy of radiotherapy for adequate 
palliation, but with divergent results and mainly based on case series [55].  
 
Other local therapies 
In case of inoperable metastatic disease, palliation is possible with local treatment 
modalities, such as radiofrequency ablation (RFA) or transarterial chemoembolization 
(TACE). None of these methods have been explored in clinical trials. However, both 
methods are an alternative to surgery, when surgery is not desired or contraindicated [3]. 
Adrenal tumours, including ACC, have a tendency to undergo hemorrhage and might lead 
to bleeding complications. 
 
 
1.10 PROGNOSTIC FACTORS AND PREDICTIVE MARKERS 
Despite the globally poor prognosis of ACC, there is a marked individual variation in 
disease progression, recurrence, and overall survival.  
Unfavourable prognostic indicators are tumour extent (e.g., stage), specifically the 
presence of metastatic disease and number of organs involved, high Weiss score, high 
tumour grade (>20 mitoses per HPF), and high Ki67 [59]. Although older studies did not 
show any differences in prognoses for patients harboring different hormone secretion 
subtypes of ACC, recent studies including a total of 274 patients identified cortisol 
production as an adverse prognostic factor [4,125].  
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Novel potential factors have been described in order to improve outcome stratification 
and to identify subpopulations of subjects in which therapies could be effective.  
Two subgroups of ACCs have been reported based on transcriptome characteristics: 
cluster C1A and cluster C1B, the latter one with a remarkable better 5-years survival rate 
(20 vs 91%) [71,72,75,131]. Genes involved in cell cycle regulation predominated in the 
poor outcome group (C1A). Moreover, all TP53 and CTNNB1 mutations were exclusively 
observed in the C1A ACC group. The C1A group was further divided into three 
subgroups, with inactivated p53 (C1A-p53), activated β-catenin (C1A-β-catenin) and one 
with a still unidentified molecular alteration (C1A-x) [132], but validation of these 
microarray based prognostic factors is needed. C1A and C1B groups differed also in 
microRNAs and DNA methylation [94].  
Barreau et al. made the first correlation between DNA methylation levels and patient 
outcome in ACC [83]. After analysis of DNA methylation profiles of a series of ACC 
samples, two groups of ACCs were identified, one exhibiting a higher methylation 
compared to ACAs, which was termed the CpG island methylation phenotype (CIMP) 
group, similarly to what previously reported in other types of cancer (e.g. colorectal 
cancer) [133]. Of note, the two ACC subgroups with poor prognosis previously identified 
as C1A-p53 and C1A-x showed a CIMP pattern. In contrast, the poor prognosis subgroup 
named C1A-β-catenin and the good prognosis C1B group belonged to the non-CIMP 
cluster [83]. The fact that not all poor prognosis groups show a CIMP could potentially 
mean that the prognostic value of methylation patterns is less effective compared to gene 
expression. The CIMP group was further divided into two subgroups, with different levels 
of methylation (CIMP-high and CIMP-low). Hypermethylation was associated with a 
poor survival [83,94]. 
Dismal prognosis of ACC is associated with overexpression of the pituitary tumour 
transforming gene 1 (PTTG1), low expression of the transforming growth factor β 
signalling mediator SMAD and diminished expression of GATA-6, cyclin E 
overproduction, and overexpression of SF1 [55]. Combined assessment of Ki67 and VAV 
2, a factor overexpressed by increased SF1 and essential for tumour spreading, improved 
prognostic prediction in ACC [134]. 
Recently, several studies have identified potential factors associated with response to 
mitotane.  CYP2W1 immunoreactivity was associated with a longer overall survival and 
time to progression in mitotane monotherapy treated patients, even when adjusted for 
ENSAT stage [135].  
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Ribonucleotide reductase large subunit 1 (RRM1) gene expression was associated with a 
shorter disease-free survival and overall survival [129]. Subjects with low RRM1 
expression who received adjuvant mitotane had a significantly longer disease-free 
survival compared to patients who only received follow-up, whereas this was not the case 
in patients with high RRM1 expression. It has been suggested that the RRM1 gene might 
interfere with mitotane metabolism in ACC cells.  
Ronchi et al. investigated protein expression of excision repair cross complementing 
group 1 (ERCC1) as a predictor for response to platinum-based chemotherapy in patients 
with ACC. High ERCC1 expression was correlated with a worse overall survival in 
patients treated with platinum-based chemotherapy [136]. 
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PART 2: VITAMIN D 
2.1 VITAMIN D AND ITS BIOACTIVATION 
Vitamin D is member of the secosteroid family widely known for its role in phosphate 
and calcium homoeostasis and its preventive action in rickets and osteomalacia by 
increasing bone mineralisation and osteogenesis. The most widely accepted physiological 
effect of vitamin D is mediated primarily by 1α,25(OH)2D3, also known as calcitriol, 
which represents the most active product of vitamin D synthesis. 1α,25(OH)2D3 is 
synthesized in a highly regulated multistep process (Figure 4).  
 
 
Figure 4. On the left, principal steps of vitamin D3 metabolism in humans [137]. On the right, 
chemical structure of 1α,25(OH)2D3 [138]. 
 
The first step in vitamin D synthesis is the formation of vitamin D3 in the skin through 
the action of ultraviolet irradiation with spectrum 280-320 nm (UVB), which transforms 
pro-vitamin D in pre-vitamin D3. Temperature-dependent isomerisation of pre-vitamin 
D3 in the basal layers of the epidermis leads to vitamin D3 (cholecalciferol).  Reduced sun 
exposure as well melanin and sunscreen limit vitamin D synthesis. Vitamin D3 can also 
be taken in the diet but in North America and Europe dietary vitamin D3 intake represents 
a minor component of vitamin D3 acquisition as it is present in only a few foods (dairy 
products, eggs, fish and fortified products) that contain only small amounts of vitamin D. 
Already formed in the skin or ingested by the diet, vitamin D3 travels through the 
bloodstream joined to DBP (vitamin D Binding Protein) and albumin, to a lesser extent. 
Both DBP-bound vitamin D and free vitamin D stay in balance to maintain adequate 
levels of the active hormone [138]. 
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Vitamin D3 itself is not biologically active. Vitamin D3 is hydroxylated at C-25 by liver 
mitochondrial and microsomal 25-hydroxylases (25-OHase) to produce 25-
hydroxyvitamin D3 [25(OH)D3]. The synthesis of 25(OH)D3 has not been reported to be 
highly regulated [139]. Many cytochrome P-450 enzymes including CYP2R1, CYP27A1, 
and CYP2D25 (among other 25 hydroxilases) have been considered as candidates for the 
enzyme responsible for the conversion of vitamin D to 25(OH)D3 [140]. The 25(OH)D3 
is the major circulating form of vitamin D and its serum concentration has served as one 
of the most reliable biomarkers of vitamin D status [138,141].  
25(OH)D3 is transported by DBP to the kidney and is filtered by the glomerulus. In the 
kidney megalin, a 600-kDa transmembrane protein, and a member of the low-density 
lipopoprotein receptor superfamily, acts as a cell surface receptor for DBP resulting in 
uptake of 25(OH)D in the tubular epithelial cells by endocytic internalization [141]. In 
the proximal renal tubule, 25(OH)D3 is hydroxylated at the position of carbon 1 of the A 
ring, resulting in the formation of 1,25(OH)2D3 (calcitriol), which is the functional, 
hormonally active form of vitamin D, responsible for most of the biologic actions of 
vitamin D. 
The renal 25(OH)D3 1α-hydroxylase (mitochondrial CYP27B1), which metabolizes 
25(OH)D3 to 1,25(OH)2D3, comprises a cytochrome P-450, a ferredoxin, and a ferredoxin 
reductase and is present predominantly in the kidney (proximal straight tubules) and 
contributes to the circulating concentrations of 1,25(OH)2D3 [142].  
In the kidney, besides conversion to 1,25(OH)2D3 by CYP27B1, 25(OH)D3 can also be 
converted to 24,25(OH)2D3 by hydroxylation at C-24 by CYP24A1 (24-hydroxylase, 24-
OHase), a mitochondrial inner membrane cytochrome P-450 enzyme [142]. This enzyme 
can hydroxylate not only 25(OH)D3 but also 1,25(OH)2D3. 1,25(OH)2D3 has been 
suggested to be the preferred substrate for CYP24A1. CYP24A1 limits the amount of 
1,25(OH)2D3 when circulating 1,25(OH)2D3 is elevated by catalysing the conversion of 
1,25(OH)2D3 into 24-hydroxylated products targeted for excretion or by producing 
24,25(OH)2D3 thus decreasing the pool of 25(OH)D3 available for 1-hydroxylation [138]. 
Additionally, 1α,25(OH)2D3 concentrations are feedback regulated: an increase in 
24,25(OH)2D3 induces the synthesis of 1α,25(OH)2D3; whereas Ca2+, Pi and 
1α,25(OH)2D3 itself suppress 1α,25(OH)2D3 synthesis. CYP27B1 (which encodes 1α-
OHase) expression is induced by parathyroid hormone (PTH) and repressed by 
1α,25(OH)2D3 [137]. Furthermore, CYP24A1 is strongly induced by 1α,25(OH)2D3 to 
produce the less active vitamin D metabolites 1α,24,25(OH)2D3 and 24,25(OH)2D3 [138]. 
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It has been suggested that in healthy animals and humans CYP27B1 is only expressed in 
kidney and, during pregnancy, in placenta. However, in addition to the kidney, it has been 
reported that CYP27B1 is present in a number of extrarenal sites. Extrarenal production 
of CYP27B1 has been convincingly demonstrated in patients with sarcoidosis [143]. 
Macrophages were identified as the source of extrarenal production of 1,25(OH)2D3 
resulting in hypercalcemia and hypercalciuria in these patients. In addition to sarcoidosis, 
hypercalcemia has also been identified in patients with Crohn’s disease [144]. It was 
suggested that activated macrophages of Crohn’s granuloma are responsible for the 
hypercalcemia in Crohn’s disease. CYP27B1 produced by macrophages, unlike renal 
CYP27B1, is not suppressed by elevated 1,25(OH)2D3 but is upregulated by immune 
stimuli [interferon-γ and lipopolysaccharide (LPS)]. Regulation by immune stimuli has 
been reported to involve multiple pathways (including JAK/STAT and NF-κB) [137]. 
Cancer cells have also been shown to express CYP27B1. In addition, CYP27B1 
expression has been noted in parathyroid gland and in many other tissues. However, 
whether there is a functional impact of CYP27B1 activity in vivo at sites other than the 
kidney and placenta under normal physiological conditions remains to be determined 
[138]. 
 
2.2 THE VITAMIN D RECEPTOR 
The biological actions of 1,25(OH)2D3 are mediated by the VDR. VDR belongs to the 
steroid receptor family which includes receptors for retinoic acid, thyroid hormone, sex 
hormones, and adrenal steroids [145]. The VDR gene is evolutionarily conserved among 
fishes, birds, and mammals. The human and mouse VDR genes are localized on 
chromosomes 12 and 15, respectively and both are comprised of eight coding exons [138].  
Human VDR protein consists of 427 aminoacids. It functions as an obligate heterodimer 
with RXR for activation of vitamin D target genes [137,145]. The two core functional 
domains of the VDR are the highly conserved NH2-terminal DNA binding domain 
(DBD), a cysteine-rich zinc finger region, and the more variable COOH-terminal ligand 
binding domain (LBD). LBD contains sequences critical for interactions with co-
regulators (Figure 5).  
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Figure 5. The vitamin D receptor and its critical regions [137]. 
1,25(OH)2D3 binding induces a conformational change that facilitates interaction with 
RXR and coregulatory complexes required for the transcription of target genes. X-ray 
crystallographic data of the VDR/RXR complex is currently not available. Recently, the 
structure of the liganded VDR/ RXR DNA complex was characterized using cryoelectron 
microscopy [138]. Recent studies using small angle X-ray scattering and hydrogen- 
deuterium exchange technology also enabled characterization of the VDR/RXR DNA 
complex and indicated cooperative effects between the VDR DBD and VDR LBD, 
suggesting mechanisms by which ligands and DNA can act together to fine-tune 
regulation of gene expression [138].  
 
2.3 GENOMIC MECHANISM OF 1,25(OH)2D3-VDR COMPLEX 
The classical genomic mechanism of 1,25(OH)2D3 action involves the direct binding of 
1,25(OH)2D3 activated VDR/RXR to specific DNA sequences known as vitamin D 
response elements (VDREs) in and around target genes (Fig. 2.3). The heterodimerization 
of 1,25(OH)2D3-VDR with RXR leads to high-affinity binding to VDREs. Following the 
binding of VDR-RXR heterodimer to the VDRE, changes in gene expression are 
mediated through the ability of the liganded receptor to recruit transcriptional coactivators 
(Figure 6). The p160 coactivators, steroid receptor activator 1, 2, and 3 (SRC-1, SRC-2, 
and SRC-3), that exhibit histone acetylase (HAT) activity, are primary coactivators which 
bind to the liganded VDR. Members of the p160 family recruit proteins as secondary 
coactivators, such as CBP/p300 (which also have HAT activity), resulting in a 
multisubunit complex that modifies chromatin and destabilizes histone/DNA interaction 
[137,146]. In addition to acetylation, methylation also occurs on core histones. Recent 
studies have shown that methyltransferases may also play a fundamental role in VDR-
mediated transcription [147,148]. VDR-mediated transcription is facilitated by Mediator, 
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a multi-protein complex (the 205 subunit binds to VDR) which functions through 
recruitment of RNA polymerase II and promotes formation of the preinitiation complex. 
A number of other transcription factors have been reported to affect the transcriptional 
activity of VDR. Since VDR coregulatory proteins are master regulators of 1,25(OH)2D3 
action, further studies identifying VDR coactivators and corepressors as well as 
epigenetic regulation of VDR function will yield significant new insight into the complex 
mechanisms by which 1,25(OH)2D3 acts to direct its multiple biological activities [147]. 
 
Figure 6. Illustration of genomic mechanism of 1,25(OH)2D3/VDR complex action (on the left side). 
Schematic view of proposed non-genomic mechanism of liganded VDR (on the right side) [149].  
 
The complexity of the molecular mechanisms involved in 1,25(OH)2D3 action is not only 
indicated by the diversity of coregulators and their activities but also through genome-
wide studies which have shown that the actions of 1,25(OH)2D3, similar to other steroids, 
involve regulation of gene activity at a range of locations many kilobases upstream as 
well as downstream of the transcription start site and within introns and intergenic 
regions. VDR binding to these sites is largely but not exclusively dependent on activation 
by 1,25(OH)2D3. Global networks regulated by VDR are beginning to be addressed in 
osteoblastic, intestinal carcinoma, immune, and hepatic stellate cells [138,148,150]. 
Genome-wide studies have provided a new perspective on mechanisms involved in the 
regulation of gene expression by 1,25(OH)2D3 and suggest a chromatin looping 
mechanism whereby the regulatory regions can be brought into close proximity with the 
gene’s promoter via protein-protein interaction [147]. 
Non-genomic actions mediated by 1,25(OH)2D3 are rapid and not dependent on 
transcription. However, non-genomic signalling may indirectly affect transcription 
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through cross-talk with other signalling pathways [137]. The most well-described non-
genomic effect of 1,25(OH)2D3 is the rapid intestinal absorption of Ca
2+. 
There is no agreement on how the non-genomic actions are initiated. Data suggest that 
these effects begin at the plasma membrane and involve a non-classical membrane 
receptor (mVDR) described in intestinal caveolae, and a 1,25(OH)2D3-membrane-
associated rapid response steroid binding protein (1α,25D3-MARRS) isolated from chick 
intestinal basal-lateral membrane, with subsequent activation of numerous signalling 
cascades [137,138]. 
 
2.4 CLASSICAL ROLES OF VITAMIN D 
2.4.1 Intestine 
The principal action of 1,25(OH)2D3 and the VDR is intestinal calcium absorption. This 
conclusion is based on the observation from patients with hereditary vitamin D-resistant 
rickets (HVDRR), a rare autosomal recessive disorder characterized by hypocalcemia, 
hyperparathyroidism, early-onset rickets, and organ resistance to 1,25(OH)2D3. 
Resistance to 1,25(OH)2D3 is caused by heterogeneous loss of function mutations in the 
VDR gene. In the setting of HVDRR, mineral and skeletal phenotypes are reversed when 
treated with intravenous or high oral calcium [151].  
The facilitated diffusion model is the most studied mechanism of vitamin D-regulated 
calcium absorption, involving stimulation of transcellular intestinal calcium transport by 
increasing the expression of the apical membrane calcium channel TRPV6 and of calcium 
binding protein calbindin-D9k. However, the fine-tuned mechanisms involved in vitamin 
D regulation of intestinal calcium absorption have remained incompletely understood. 
Moreover, it has been suggested that 1,25(OH)2D3 can also stimulate active phosphate 
absorption in the intestine [138] (Figure 7). 
 
 
Figure 7. Effects of 1,25(OH)2D3 on calcium absorption in the intestine cells [138]. 
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Most of what is known about intestinal calcium absorption mediated by 1,25(OH)2D3  
comes from studies that utilize the duodenum. However, even though the high efficiency,    
only 8-10% of calcium absorption takes place in this tract. Although little is known about 
1,25(OH)2D3 action in other parts of the intestine, distal segments of the intestine are 
suggested to play an important role in intestinal calcium absorption and proper bone 
mineralization. Vitamin D and 1,25(OH)2D3-regulated calcium transport has been 
reported in ileum, cecum, and colon [152]. 
In addition to transcellular transport, calcium is absorbed by the paracellular path that 
occurs between epithelial cells. To date, little is known about the vitamin D dependency 
of this non-saturable component of calcium absorption recently suggested [153].  
 
2.4.2 Kidney 
Only 1% to 2% of filtered calcium appears in the urine. Approximately 65% of the filtered 
calcium is passively reabsorbed at the proximal tubules in a 1,25(OH)2D3-independent 
way. The proximal tubules of the kidney are the major site of 1,25(OH)2D3 synthesis and 
of phosphate absorption . CYP27B1 expression is upregulated by PTH but downregulated 
by FGF23 and 1,25(OH)2D3. Phosphate reabsorption in the proximal tubules is regulated 
by several factors including FGF23, PTH, and 1,25(OH)2D3 [138]. 
In the distal tubules, calcium absorption is regulated by 1,25(OH)2D3 and PTH, involving 
TRP channels (transient receptor potential cation channels), especially TRPV5, as active 
transcellular mechanism that resembles intestinal calcium absorption [154]. 
 
2.4.3 Bone 
Bone formation involves the mineralization of the extracellular matrix formed by 
osteoblasts. In this process the role of 1,25(OH)2D3 is both direct and indirect.  
Indirect effects occur via control of calcium and phosphate absorption in the intestine and 
renal reabsorption of calcium  [155]. In VDR knockout mice, a rescue diet containing 
high levels of calcium and phosphorus prevents rickets and osteomalacia, but did not 
rescue all bone defects. This suggests the importance of the direct role of 1,25(OH)2D3 
for bone mineralization [156].  
Direct effects of 1,25(OH)2D3 are targeted to bone forming cells (osteoblasts) to enhance 
differentiation and mineralization, as was found in in vitro cultures using human 
osteoblasts [157]. Direct effects of vitamin D on osteoblasts are exerted by binding to the 
nuclear VDR [158]. However, differences occur in VDR protein expression during 
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osteoblast development. In fact, VDR is highly expressed in immature osteoblasts, while 
low or no expression is detected in matured osteoblasts, including lining cells and 
osteocytes [159].  
Direct effects of 1,25(OH)2D3 on osteoblasts involve the control of the production of 
extracellular matrix proteins (collagen type I, osteopontin, osteocalcin, matrix Gla 
protein) and effects on the activity of the alkaline phosphatase enzyme to supply 
phosphate for the deposition of mineral [160]. Woeckel et al. showed that 1,25(OH)2D3 
positively interferes in the mineralization process of human osteoblasts by accelerating 
their production of alkaline phosphatase positive extracellular vesicles [157,160] 
eventually resulting in an increased formation and deposition of hydroxyapatite crystals 
leading to increased mineralization. This direct effect of vitamin D occurred early, in the 
period prior to the onset of mineralization and involved also an accelerated extra cellular 
matrix maturation [157]. Direct effects of 1,25(OH)2D3 on human osteoblast activity 
depend on phase of differentiation of osteoblasts, thus different features of vitamin D 
action may take place during different stages of differentiation. 
VDR expression was found in hypertrophic chondrocytes, and not in osteoclasts, 
chondroclasts and bone marrow stromal cells. The VDR absence in osteoclasts may 
indicate that the effects of 1,25(OH)2D3 on osteoclast differentiation are indirect via 
increasing the expression of receptor activator of NF-κB ligand (RANKL) in osteoblasts, 
which is an important osteoclastogenic factor. RANKL binds to its cognate receptor 
RANK in osteoclast precursors and increases osteoclast formation and action [138]. 
Human osteoblasts express 1α-hydroxylase (CYP27B1) as well as the vitamin D binding 
protein receptors cubulin and megalin to metabolize 1,25(OH)2D3 that is active in 
stimulating differentiation and mineralization. Besides the advantages of this local 
1,25(OH)2D3 production to the bone, also the precursor 25(OH)D3 as well as the 24-
hydroxylated ‘degradation’ products 24R,25(OH)2D3 and 1,24R,25(OH)3D3 are 
stimulatory to osteoblast differentiation and mineralization in human preosteoblasts and 
mesenchymal stem cells [161].  
Understanding the exact role of vitamin D in this process remains difficult to achieve, 
since vitamin D effects are part in many networks. The differences in experimental 
conditions used in combination with the different models used in studying vitamin D 
further contribute to the complexity, and require careful interpretation of the data [160]. 
 
43 
 
2.5 PLEIOTROPIC EXTRA-SKELETAL ACTIONS OF VITAMIN D 
In addition to its role in calcium and bone homeostasis, vitamin D potentially regulates 
many other cellular functions. The vitamin D receptor (VDR) is nearly universally 
expressed in nucleated cells. Furthermore, at least 10 tissues outside the kidney express 
1-alpha-hydroxylase (CYP27B1), the enzyme responsible for converting vitamin D to its 
active form, and therefore, the active hormone can be generated in an auto- or paracrine 
way. In other words, now the concept is that all cells may be targets for 1,25(OH)2D3, at 
least at some stage of their differentiation, and that many of these cells make their own 
1,25(OH)2D3 and are not totally dependent on the renal production of this metabolite. 
Thus, the spectrum of activity of the vitamin D endocrine system is much broader than 
calcium/bone homeostasis. In this regard, the vitamin D-VDR system resembles that of 
other ligands of nuclear receptors, such as thyroid hormone [162-164].  
 
2.5.1 Muscle and falls 
A body of evidence suggest a relationship between vitamin D and muscle function [165]. 
In humans vitamin D deficiency leads to a preferential loss of type II muscle fibers 
associated with fatty infiltration, fibrosis, and loss of strength, and is associated with 
muscle weakness and increased falls [164,165]. VDR and CYP27B1 expression decreases 
with differentiation of muscle precursor cells into adult fibres; however, in adult muscle 
VDR is still expressed albeit at very low levels [166]. The non-genomic actions of 
1,25(OH)2D3 have also received attention in muscle. Vitamin D supplementation 
improved muscle weakness and recovery of energy stores (maximal mitochondrial 
oxidative phosphorylation rate, as measured by in vivo magnetic resonance spectroscopy) 
after physical exercise in severely vitamin D-deficient but otherwise healthy adults [167]. 
Observational studies suggest an association between poor vitamin D status (<10 or <20 
ng/mL [<25 or <50 nmol/L]) and muscle weakness in children and older individuals 
[162,168,169]. However, a causal relationship between vitamin D supplementation and 
improvement in muscle weakness has not been clearly demonstrated in randomized trials, 
and the optimal 25-hydroxyvitamin D3 (25[OH]D3) concentration for muscle function is 
still unknown [168]. Probably, benefit of vitamin D supplementation on muscle strength 
occurs when baseline 25(OH)D3 levels are below 10 or 20 ng/mL (25 or 50 nmol/L). 
Efforts to provide very large doses of vitamin D (or calcifediol) at infrequent intervals 
(e.g., 500,000 IU annually or 60,000 IU every month) have not been successful and may 
even increase the fall risk [170]. 
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2.5.2 Cardiovascular system 
In vitro studies show that 1,25(OH)2D3 suppresses myocyte hypertrophy, 1,25(OH)2D3 
suppresses endothelin expression in cardiac fibroblasts, a known profibrotic/hypertrophic 
factor for the heart, whereas the expression of several metalloproteinases are increased 
and their inhibitors are decreased. VDR- and CYP27B1-null mice have increased levels 
of renin, increased blood pressure, increased cardiac hypertrophy, impaired systolic and 
diastolic function, increased arterial stiffness, and reduction in nitric oxide synthase 
(NOS) activity [164,171]. VDRKO mice are prone to develop accelerated atherosclerosis, 
whereas 1,25(OH)2D3 can reduce such lesions in ApoE gene knockout mice, a mouse 
model of accelerated atherosclerosis, in part by suppressing the immune response in the 
atherosclerotic plaques. 1,25(OH)2D3 showed promising results in mouse models of 
hypertension, such as reduction of procoagulant status [164]. 
Severe vitamin D deficiency is associated with cardiomyopathy and congestive heart 
failure in children, which are reversible with vitamin D supplementation [164]. 
Epidemiologic studies investigated the relationship between low 25(OH)D3 levels and 
increased risk of cardiac events,  strokes, coronary artery calcification, and atherosclerosis 
in various settings. Not all such studies are positive but recent metanalyses of a number 
of these studies have demonstrated an association [172,173].  Endothelial function was 
found to improve in vitamin D–deficient diabetic patients when given vitamin D. 
However, RCTs have generally been disappointing [174].  
The potential benefit of vitamin D supplementation on prevention and treatment of 
cardiovascular disease needs confirmation.  
 
2.5.3 Immune system 
The overall picture is that vitamin D signalling suppresses adaptive immunity but 
promotes innate immunity. The VDR and CYP27B1 are expressed in most if not all cells 
of the immune system including the epithelial cells at least when activated [164]. 
Moreover, several of these cells express CYP2R1 and so theoretically can produce 
1,25(OH)2D3 from circulating vitamin. The regulation of CYP27B1 in these cells differs 
substantially from that in the kidney, being insensitive to hormonal regulators such as 
PTH and FGF23, its product 1,25(OH)2D3, and calcium and phosphate levels. In these 
immune cells, CYP27B1 is stimulated by cytokines such as TNF-α and interferon-γ (IFN-
γ) [164]. Furthermore, transcription of the enzyme that controls 1,25(OH)2D3 levels 
within cells, CYP24A1, is absent, defective, or blocked, essentially leaving 1,25(OH)2D3 
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with minimum regulation. Thus, activation of these immune cells in diseases such as 
sarcoidosis or lymphomas can lead to hypercalcemia with elevated 1,25(OH)2D3 levels 
[143].  
The relevance of 1,25(OH)2D3 on the immune system has been suggested by in vivo 
studies in mouse models of autoimmunity. 1,25(OH)2D3 can protect against a number of 
experimental autoimmune diseases including inflammatory bowel disease and 
experimental autoimmune encephalomyelitis (mouse model for multiple sclerosis) [138]. 
Studies on animal experimental models of rheumatoid arthritis, psoriasis, type 1 diabetes 
mellitus, systemic lupus erythematosus, multiple sclerosis, and inflammatory bowel 
disease have been ameliorated with the use of 1,25(OH)2D3 or one of its analogues [138]. 
Association studies in humans have found inverse correlations between 25(OH)D3 levels 
and/or vitamin D intake and a number of autoimmune diseases, including multiple 
sclerosis, type 1 diabetes, Crohn’s disease, rheumatoid arthritis, lupus, and Graves 
thyroiditis. Although experimental findings are suggestive of a protective effect of 
1,25(OH)2D3 against the pathogenesis of autoimmune inflammation, whether vitamin D 
supplementation or treatment with analogues of 1,25(OH)2D3 is beneficial clinically in 
the treatment of autoimmune diseases is not known [164]. 
 
2.5.4 Skin  
The epidermis is the major source of vitamin D3 in the body. Keratinocytes, having the 
25-hydroxylase CYP27A1, possibly CYP2R1, the 1α-hydroxylase CYP27B1, and the 
VDR, can make their own 1,25(OH)2D from their own substrates and respond to the 
1,25(OH)2D3 they produce. The highest levels of VDR and CYP27B1 are found in the 
basal stratum. The VDR is also highly expressed in the stem cells of the hair follicle. 
1,25(OH)2D3 ligand-dependent VDR transcriptional activity promotes differentiation of 
keratinocites by blocking β-catenin regulated proliferation. Coactivator complexes 
control different aspects of VDR action in keratinocytes, with Mediator 1 more involved 
in proliferation, whereas SRC2 and SRC3 more involved in maintenance of the barrier 
function of the skin including its innate immune function [175].  
Vitamin D suppresses the immunologic aspects of psoriasis, a complex disease of 
autoimmunity characterised by skin hyperproliferation, and 1,25(OH)2D3 have a well-
validated clinical application in this setting. In fact, a number of clinical trials have 
demonstrated the efficacy and safety of 1,25(OH)2D3 and its analogues in the treatment 
of psoriasis, as monotherapy or in combination with topical glucocorticoids [164]. 
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2.5.5 Type 2 diabetes mellitus 
Pancreatic β-cell expresses both VDR and CYP27B1. 1,25(OH)2D3 stimulates insulin 
secretion in vivo and in vitro, and promotes glucose uptake by peripheral tissues. Calcium 
levels seem to be important in determining impaired insulin secretion in in vitamin D 
deficiency and in VDRKO mice [164]. The renin/angiotensin system (RAS) may also 
play a role by impairing β-cell function and insulin sensitivity. Several clinical studies 
investigated the relationship between increased risk of type 2 diabetes mellitus with low 
25(OH)D3 levels, but not all studies showed this association [164,176]. A large 
multicentre placebo-controlled RCT is ongoing to study the role of vitamin D in type 2 
diabetes mellitus [176]. 
 
2.5.6 Obesity 
The adipocyte expresses both the VDR and CYP27B1 [138]. The role of vitamin D in 
adipogenesis depends on species and stage of cell differentiation by processes involving 
Wnt/β-catenin signalling.  
Vitamin D deficiency is very common in obese patients, probably due to a sum of factors 
including increased storage in fat tissue, decreased sunlight exposure, and decreased 
efficiency of vitamin D production in the skin. Clinical trials with vitamin D and calcium 
have had limited success with respect to reducing obesity or increasing energy 
expenditure [164].  
 
 
2.6 VITAMIN D AND CANCER 
2.6.1 Epidemiological data 
The inverse relationship between solar exposure and cancer mortality in North America 
was first noted by Apperly [177] in 1941. This association was related to ultraviolet B 
exposure as the protective element by the Garland brothers in 1980 in their epidemiologic 
studies with colon cancer, introducing the possible link with vitamin D status. With the 
exception of skin cancer, the inverse relationship between solar exposure and cancer has 
been described for many other cancer types in several countries [178].  
There is now a very extensive medical literature on vitamin D and cancer epidemiology. 
Most of the studies have focused on epithelial cancers, i.e. colorectal, breast, and prostate 
cancer.   
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Colon cancer  
Observational studies in humans (cross-sectional studies and especially long-term, 
prospective studies) revealed a link between poor vitamin D status (either evaluated by 
serum 25(OH)D3 or a surrogate estimation) and the risk of nearly all cancers [178,179], 
but a reanalysis by a World Health Organization (WHO) working group identified colon 
cancer as the greatest risk associated with poor vitamin D status. This finding was 
supported by the results of a meta-analysis of nine case-control studies [180]. For each 4 
ng/mL (10 nmol/L) increase in prediagnosis serum 25(OH)D3 concentration, there was a 
6 percent (95% CI 3-9 percent) reduction in colorectal cancer risk. In one of the largest 
studies in the meta-analysis, a nested case-control study in European populations 
including 2496 cases and controls, serum 25(OH)D3 levels between 10 and 20 ng/mL (25 
to 50 nmol/L) compared with 20 to 30 ng/mL (50 to 75 nmol/L) were associated with a 
higher incidence of colorectal cancer (incidence rate ratio 1.28, 95% CI 1.05-1.56) [181]. 
In contrast to these results, a prospective case-control study did not show a significant 
association between vitamin D status and colon or colorectal cancer [182]. In addition, 
some observational studies have shown an elevated risk of some cancers (i.e., pancreatic) 
at higher 25(OH)D3 levels (relative risk [RR] 2.12, 95% CI 1.23-3.64 for levels ≥40 
versus 20 to 30 ng/mL [≥100 versus 50 to 75 nmol/L]) [183]. 
Breast cancer  
Observational studies examining the relationship between vitamin D and breast cancer 
report inconsistent results. A meta-analysis of prospective studies examining the 
relationship between serum 25(OH)D3 concentrations and breast cancer risk showed a 
significant inverse association in post- but not premenopausal women [184]. The risk of 
postmenopausal breast cancer decreased with 25(OH)D3 levels between 27 and <35 
ng/mL (67 to 87 nmol/L), with no further reduction for levels above 35 ng/mL.  
A metanalysis of 8 case control studies demonstrated an OR of 0.55 (CI 0.38–0.80) 
comparing the highest quintile of  25(OH)D3 levels to the lowest. In general, these studies 
did not evaluate premenopausal and postmenopausal women separately [164]. 
Chlebowski performed a similar review of 10 case control and 10 cohort studies with 
respect to vitamin D intake and breast cancer and 4 case control and 6 nested case control 
studies with respect to 25OHD levels and breast cancer [185]. A meta-analysis of five of 
the case control studies examining vitamin D intake failed to show a significant effect of 
vitamin D overall, but when only the premenopausal/perimenopausal women were 
included in the analysis a significant negative association between increased intake and 
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breast cancer incidence was found (RR 0.83, CI 0.73–0.95). Of the six nested case control 
studies assessing the relationship of serum 25(OH)D3 and breast cancer, only one study 
showed a significant negative association between high 25(OH)D3 levels and incidence 
of breast cancer, although one other study was close (P = 0.06). In a separate metanalysis 
by Gandini et al., a RR of 0.89 (0.82–0.98) for a 10 ng/ml increase in 25(OH)D3 was 
found when all studies were included and 0.83 (0.79–0.87) when only case control studies 
were pooled. Epidemiologic data tend to support a protective role for vitamin D and breast 
cancer, but the data are not as compelling or consistent as for colorectal cancer [178]. 
Prostate cancer  
A relationship between serum 25(OH)D3 levels and prostate cancer incidence has not 
been consistently found. In observational studies, higher (highest compared with lowest 
quartiles or quintiles) serum 25(OH)D3 levels have been associated with both an increased 
and reduced risk of more aggressive disease [186]. A meta-analysis of six cohort/nested 
case control studies (8,722 cases) examining the association of dietary vitamin D intake 
to prostate cancer found a relative risk of 1.14 (CI 0.99–1.31) for an increase in dietary 
vitamin D of 1,000 IU. Similarly, a meta-analysis of 14 cohort/nest case control studies 
including 4,353 cases examining the association of serum 25(OH)D3 and prostate cancer 
found a relative risk of 1.04 (CI 0.99–1.1) for a 10 ng/ml increase in 25(OH)D3 for all 
prostate cancers. Likewise, no association was found for serum 1,25(OH)2D3 levels [187]. 
Similar negative results were observed in the meta-analysis by Gandini et al [178]. 
Although an initial clinical trial (ASCENT I) with high dose 1,25(OH)2D3 and docetaxol 
seemed to show promise in the treatment of castration resistance prostate cancer, this 
initial success could not be repeated in a larger trial (ASCENT II) potentially flawed by 
a change in the docetaxol only arm of the study  [164]. Thus, the clinical evidence weighs 
against vitamin D being beneficial in the prevention/treatment of prostate cancer. 
2.6.2 Intervention trials 
The majority of vitamin D intervention trials do not show a reduction in cancer risk [187]. 
In a meta-analysis of 18 randomized trials in predominantly older, community-dwelling 
women, vitamin D supplementation had no effect on the incidence of cancer [188]. In a 
trial published after the meta-analysis, 2303 healthy, postmenopausal women (mean 
baseline 25(OH)D3 32.8 ng/mL [81.9 nmol/L]) were randomly assigned to 2000 
international units vitamin D3 and 1500 mg of calcium daily or identical placebos]. After 
four years, the proportion of patients in each group with newly diagnosed cancer did not 
49 
 
significantly differ (3.89 and 5.58 percent, respectively, hazard ratio [HR] 0.70, 95% CI 
0.47-1.02) [189]. An analysis by cancer site showed no difference in the incidence of 
breast cancer between the two groups; there were too few cancers at other sites to analyze. 
Study limitations include selection of patients with a relatively high baseline vitamin D 
level and permission to supplement with vitamin D (up to 800 international units daily) 
outside of the intervention, both of which may have contributed to the absence of an 
effect. Additional trials are ongoing [164,189]. 
To date, the relationship between cancer and vitamin D remains controversial. The expert 
panel of the Institute of Medicine (IOM) declared that the data were inconclusive as to 
whether vitamin D had a protective role in cancer [178]. Indeed, clinical data are mixed, 
and definitive evidence from randomized clinical trials is lacking. Given the lack of 
funding support for a sufficiently large trial, such evidence may be difficult in the near 
future.  
 
2.6.3 Cellular mechanisms by which vitamin D is supposed to be an anticancer agent  
1,25(OH)2D3 regulates the expression of hundreds of genes, both those encoding mRNAs 
that are translated into proteins and those encoding RNA that are non (miRNAs, 
lncRNAs). Different cell types exhibit different profiles of genes that are regulated by 
1,25(OH)2D3, so that generalisations are difficult to make. Nevertheless, there are a 
number of cellular pathways that contribute to vitamin D regulation of cancer growth and 
metastasis that are found in several cancers. Mechanisms are summarised in Table 4. 
 Table 4. Mechanisms of vitamin D tumour suppression (modified from [178]). 
Antiproliferation  1. Arrest of cell cycle: G0/G1 and G1/S 
2. Dephosphorilation of FOXO 
3. ↓ level of myc, fos, jun 
4. ↓ activity of growth factors: IGF-I, IHH, EGF 
5. ↑ activity of TGFβ 
6. ↓ activity Wnt/β-catenin signalling 
7. Regulation of miRNA and lncRNA 
Apoptosis 1. ↑ expression GOS 2 and Bax, ↓expression Bcl2 and Bcl-XL 
2. ↑ expression DAP-3, CFKAR, FADD, ↓ caspases  
3. ↑ expression PTEN 
4. ↑ autophagy 
DNA repair 1. ↑ clearance of CPDs and 6,4-PPs (in UVB irradiated skin) 
2. ↓ oxidative DNA damage by ↑ expression antioxidant enzymes 
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3. ↑ expression of DNA repair enzymes XPC and DDB2  
Prostaglandin 
metabolism 
1. ↓ COX2 expression 
2. ↓ PG receptors 
3. ↑ 15-PDGH expression 
Angiogenesis 1. ↓ proliferation of endothelial cells 
2. ↓ VEGF expression 
Invasion and 
Metastasis 
1. ↓ Cell migration and invasion capacity 
2. ↓ expression of laminin and its receptors 
3. ↑ expression of E-cadherin 
4. ↓ expression of CEACAMI 
 
Antiproliferation 
1,25(OH)2D3 is antiproliferative for most cellular types. 1,25(OH)2D3 typically causes 
arrest at the G0/G1 and/or G1/S transitions in the cell cycle. This is associated with a 
decrease in cyclins and an increase in the inhibitors of the cyclin-dependent kinases 
(CDK) such as p21cip1 and p27kip1 again in a cell specific fashion. The antiproliferative 
actions of 1,25(OH)2D3 and its induction of p21
cip1 in colorectal cancer cell lines are 
dependent on the expression of the calcium sensing receptor [190].  Forkhead box O 
(FOXO) proteins are transcription factors that control proliferation. 1,25(OH)2D3 
promotes the interaction between several of the FOXOs with VDR and FOXO regulators 
such as SIRT1 and protein phosphatase 1, keeping FOXO dephosphorylated and in the 
nucleus in order to suppress genes involved with proliferation. Levels of other genes 
linked to proliferation such as MYC, FOS, and JUN are also decreased by 1,25(OH)2D3 
[191]. Insulin like growth factor (IGF) is a growth promoter in several tumours. 
1,25(OH)2D3 stimulates the expression of IGF binding protein 3 (IGFBP3), which binds 
IGF I and II, limiting their proliferative effects. TGFβ2 is an antiproliferative factor in 
epithelial cells. 1,25(OH)2D3 stimulates the expression of TGFβ2 as well as the TGFβ 
receptors in a number of cell types including breast and prostate cancer cells [192]. 
Hedgehog (HH) signalling promotes proliferation, and its overexpression is a major cause 
of basal cell carcinoma. Expression of components of the HH pathway such as SHH and 
GLI1 is suppressed by 1,25(OH)2D3. 1,25(OH)2D3 inhibits EGF promotion of 
proliferation by targeting the EGF/EGFR complex to endosomes and inhibiting the 
expression of EGFR [178]. Mutations in APC, leading to over activation of the Wnt/β-
catenin pathway, are the cause of most colorectal cancers. When β-catenin binds to 
TCF/LEF sites in the nucleus, proliferation is stimulated. 1,25(OH)2D3/VDR competes 
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with TCF/LEF for binding to β-catenin so, binding of β-catenin to VDR may promote 
differentiation. Moreover, 1,25(OH)2D3/VDR stimulates the expression and translocation 
(with calcium) of E-cadherin to the cell membrane where it forms a complex with β-
catenin and other catenins again promoting differentiation. The ability of 1,25(OH)2D3 to 
increase intracellular calcium contributes to these actions of 1,25(OH)2D3 by increasing 
E-cadherin expression and reducing the induction of cyclin D1 [164].  
 
Apoptosis 
1,25(OH)2D3 promotes the apoptosis of a number of cell types. These actions are 
accompanied by increased expression of the pro-apoptotic genes G0S2 (G0/G1 switch 
gene 2) and Bax with suppression of the proapoptotic genes Bcl2 and Bcl-XL [193]. Other 
pro-apoptotic genes induced by 1,25(OH)2D include death-associated protein-3 (DAP-
3), caspase 8 apoptosis-related cysteine peptidase (CFKAR), Fas-associated death 
domain (FADD), and a number of caspases (i.e., caspase 3, 4, 6, and 8). 1,25(OH)2D3 
sensitizes cells to apoptosis induced by reactive oxygen species (ROS) and cytokines (i.e., 
TNF-α). By promoting both calcium influx and release from intracellular stores, 
1,25(OH)2D3 induces apoptosis by activating the calcium-dependent µ-calpain and 
calcium/calpain-dependent caspase 12. Normal cells are protected by the presence of the 
calcium-binding protein CaBP28k, which acts as a calcium buffer in cells and that are less 
abundant in a number of cancer cells. By inducing PTEN (phosphatase and tensin 
homolog), 1,25(OH)2D3 inhibits PI3K and so reduces Akt activation, increasing BAX 
activity and so promoting apoptosis. Finally, 1,25(OH)2D3 has been shown to stimulate 
autophagy in some cancer cells in part by inhibiting the anti-autophagy gene mTOR and 
increasing the levels of the pro-autophagy gene BECLIN-1  [138,178,194]. 
 
DNA repair 
Oxidative stress is the major cause of DNA damage in tissues other than the skin, which 
is exposed to the direct damage by UVB radiation that induces the formation of 
cyclobutane pyrimidine dimers (CPD) and pyrimidine (6-4)pyrimidone photoproducts (6-
4PP). Preventing DNA damage from producing DNA mutations is the role of DNA 
damage repair (DDR), operating through mechanisms involving damage recognition, 
repair, and signal transduction. 1,25(OH)2D3 topically applied protects the skin from 
UVB-induced photodamage including increased clearance of CPDs, decreased apoptosis, 
increased survival, and increased expression of p53 [178,195]. In keratinocytes 
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1,25(OH)2D3 reduces Poly-ADP-ribose polymerase (PARP) activity, a protein involved 
with DNA breaks. In various tissues, vitamin D deficiency is associated with increased 
frequency of chromosomal damage due to oxidative and other stresses. In humans, 
vitamin D deficiency is associated with increased levels of 8-OH-20-deoxyguanosine (8-
OHdG), a marker of oxidative DNA damage, whereas vitamin D supplementation reduces 
these levels. Moll et al. found that 1,25(OH)2D3 induces two genes important for DDR: 
XPC (xeroderma pigmentosum complementation group C) and DDB2 (damage-specific 
DNA binding protein 2 also known as XPE) [196]. VDR agonists also induce the DNA 
repair protein GADD45 (growth arrest and DNA-damage inducible). Other anti-oxidative 
enzymes induced by 1,25(OH)2D3 include thioredoxin reductase 1, superoxide dismutase, 
glucose-6 phosphate dehydrogenase, and glutathione peroxidase [147,178].  
 
Prostaglandin metabolism 
Prostaglandin (PG) production is associated with cancer growth and metastasis. The 
enzymes responsible, cyclo-oxygenase (COX) 1 and 2 are induced by a variety of tumour 
promoters. 1,25(OH)2D3 at least in some cancer cell lines suppresses COX2 expression 
synergistic with NSAIDs and that of PG receptors, while increasing the expression of 15-
PGDH (hydroxyprostaglandin dehydrogenase 15-NAD), the enzyme that inactivates PGs 
[164,197]. 
 
Angiogenesis 
Angiogenesis is critical for tumour growth and metastasis. Vascular endothelial growth 
factor (VEGF) is the major stimulator of angiogenesis. VEGF production is generally 
induced in hypoxic states by hypoxia-induced factor-1α (HIF-1α). 1,25(OH)2D reduces 
hypoxia-induced expression of VEGF in a variety of cancer cell lines at least in part by 
reducing the expression of HIF-1α. In addition, 1,25(OH)2D3 inhibits the proliferation of 
endothelial cells and reduces VEGF-induced endothelial cell sprouting and elongation 
resulting in tumours with decreased vascularization [137,198].  
 
Inhibition of metastasis 
In addition to reducing the blood supply to the tumour, 1,25(OH)2D3 reduces the 
migration and invasion capacity of tumour cells [137,164]. This is facilitated by down 
regulation of the matrix protein laminin and its receptors α6 and β4, and induction of E-
cadherin that contrast the ability of cancer cells to bind to endothelial cells, necessary for 
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metastasize. 1,25(OH)2D3 also reduces the expression of (carcinoembryonic antigen-
related cell adhesion molecule 1 (CEACAM1) by endothelial cells again reducing 
metastasis. 1,25(OH)2D3 degradation of the matrix by cancer cells, limiting the activity 
of matrix metalloproteinases and cathepsins by inducing their inhibitors [138,199]. 
 
Regulation of miRNA and lncRNA 
VDR binding sites in the genome are numbered in the thousands and VDR coding 
transcripts number in the hundreds. A relevant level of regulation occurs via microRNAs 
(miRNAs) and long noncoding RNAs (lncRNAs), a difference being that miRNAs are 
typically around 20 nucleotides in length, whereas lncRNAs are 200 or more nucleotides. 
A number of miRNAs have been identified to be regulated by 1,25(OH)2D3–VDR and 
important for its antiproliferative actions. These include increased expression of miR145, 
which blocks the expression of E2F3, a key regulator of proliferation, or miR-32 that 
blocks the proapototic protein BIM, which paradoxically protects the cell (human 
myeloid leukemia) from AraC-induced apoptosis [138,200]. In VDR-null (Vdr−/−) 
keratinocytes, a number of oncogenic lncRNAs are increased, whereas tumour suppressor 
lncRNAs are decreased [201]. 
 
Alterations in VDR levels and vitamin D metabolism 
Most tumours express the VDR, and mutations in the VDR are uncommon [164,202]. 
However, the expression of the VDR is often lost as a tumour undergoes progressive 
dedifferentiation, and loss of its expression in a tumour is a bad prognostic sign. Similarly, 
CYP27B1 [25(OH)D3 1α-hydroxylase] is expressed in many tumours at early stages of 
development and mutations are uncommon but like the VDR, expression of CYP27B1 
typically declines with progressive dedifferentiation [137,138]. On the other hand, 
CYP24A1 [25(OH)D3 24-hydroxylase] expression is often increased in tumours, 
effectively reducing the levels of 1,25(OH)2D3 in the tumour microenvironment, and thus 
explaining tumour resistance to 1,25(OH)2D3 [137,178,194]. This increase is secondary 
to the CYP24A1 gene being part of a region of gene duplication seen in some tumours; its 
overexpression is a poor prognostic sign [138].  
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PART 3: VITAMIN D, EPIGENOME, AND CANCER 
 
Epigenetics is the study of heritable changes in gene expression that cannot be explained 
by changes in DNA sequence [203]. Epigenetics has become a topic of growing interest 
in recent years, since a body of evidence showed that epigenetic processes are responsible 
for global and local condensed or decondensed chromatin states that eventually determine 
gene expression, definitely resulting crucial for cell identity and functions. Epigenome, 
or ‘epigenetic landscape’, refers to the epigenetic status that determines the way a single 
eukaryotic genome may manifest itself [204].   
The first identified mechanisms of epigenetic regulation included DNA methylation and 
covalent histone modifications. DNA methylation usually occurs at the 5′ position of the 
cytosine ring within CpG dinucleotides, and its consequence is the silencing of genes and 
noncoding genomic regions. Most CpG sites are concentrated either in CpG islands, short 
CpG-rich DNA regions located in approximately 60% of human gene promoters, or in 
regions of large repetitive sequences (i.e., centromeres and retrotransposon elements) 
[205]. Modifications in DNA methylation are performed mainly by DNA 
methyltransferases (DNMTs) and ten-eleven translocation (TET) proteins. A plethora of 
enzymes, such as histone acetyltransferases (HATs), histone deacetylases (HDACs), 
histone methyltransferases (HMTs), and histone demethylases (HDMs) regulate covalent 
histone modifications that may result in both gene activation or silencing [206]. 
The epigenetic regulatory system is often disturbed in cancer [207,208]. Global DNA 
hypomethylation and promoter-specific hypermethylation are typical features of 
epigenome disruption in cancer cells. Loss of global methylation may lead to 
chromosomal instability, loss of imprinting, and activation of transposable elements, 
thereby leading to disturbances in the genome [209]. Conversely, hypermethylation of 
promoter regions of tumour suppressor genes leads to loss of expression of key genes 
affecting pathways involved in maintenance of cellular functions, including cell cycle, 
apoptosis, and DNA repair [210,211] (Figure 8). Several bona fide tumour suppressor 
genes are silenced by promoter hypermethylation in tumours [194,209]. 
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Figure 8.  Simplified illustration of DNA methylation ant its main effect. Many genes in the human 
genome have upstream CG-rich regions called CpG islands. DNA methylation of a gene's CpG island 
represses gene expression.  
 
Vitamin D can interact with the epigenome on multiple levels, with potential impact in 
health and disease [148]. Firstly, there is recent evidence that certain VDR ligands have 
DNA demethylating effects. Secondly, VDR protein physically interacts with coactivator 
and corepressor proteins, which in turn are in contact with chromatin modifiers, such as 
HATs, HDACs, HMTs, and with chromatin remodelers. Generally, HATs are defined as 
activators of transcription, whereas HDACs as transcription repressors. Thirdly, a number 
of genes encoding for chromatin modifiers and remodelers, such as HDMs of the Jumonji 
C (JmjC)-domain containing proteins and lysine-specific demethylase (LSD) families are 
primary targets of VDR and its ligands. Finally, critical genes in the vitamin D signalling 
system, such as those coding for vitamin D receptor (VDR) and the enzymes 25-
hydroxylase (CYP2R1), 1α-hydroxylase (CYP27B1), and 24-hydroxylase (CYP24A1) 
have large CpG islands in their promoter regions and therefore can be silenced by DNA 
methylation [147].  
 
3.1 Effect of vitamin D on DNA methylation 
There is evidence that 1,25(OH)2D3 is able to induce DNA demethylation, but it is not 
clear if vitamin D-induced demethylation is a passive or an active process. The fact that 
vitamin D can alter methylation of DNA in the promoter of certain genes is novel.   
Tapp et al. found a negative association between serum 25(OH)D3 levels and CpG Islands 
(CGI) methylation of the adenomatous polyposis coli (APC) promoter region, a tumour 
suppressor gene often inactive in colorectal cancer [212]. In the same study they 
highlighted a weak positive correlation of vitamin D level with methylation of the 
mammalian autonomous retrotransposon LINE-1 (genomic long interspersed nuclear 
element-1), increasing stability of this region. 
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In the setting of colorectal cancer, Rawson et al. reported that a high dietary vitamin D 
intake was associated with lower methylation of two Wnt-antagonists DIKKOPF1 
(DKK1) and WNT5A, commonly deregulated in colorectal cancer; this relationship was 
observed only in early stage tumours [213].  
Treatment of the triple negative breast cancer cell line DA-MB-231 with 1,25(OH)2D3 
reduced DNA methylation of the promoter of E-cadherin, a  cohesive molecule that 
prevents invasion and distant spread of malignant cells [214].  
 
 
3.2 Interactions of vitamin D with chromatin modulators and remodelers 
The chromatin context can alter nuclear receptor binding, determining which epigenetic 
modifications will occur thereafter. Unliganded VDR is able to bind genomic DNA, 
where it usually forms complexes with corepressor proteins that either exert HDAC 
activity, e.g., ALIEN [215],  or are associated with HDACs, such as NCOR1 and SMRT. 
Upon binding of 1,25(OH)2D3 with VDR/RXR, the corepressors dissociate and are 
replaced by coactivator complexes, which include histone acetyltransferases (HATs). As 
known, acetylation of histones enables chromatin relaxation and gene transcription. Many 
of the coactivators recruited by the VDR, including p160 steroid receptor coactivator 
proteins (SRC1, 2, and 3), p300, or CBP have lysine acetyltransferase activity [147] 
(Figure 9). 
 
 
Figure 9. Simplified illustration of a two –step coregulatory model. Acetylation of histones (black 
circles) is indicated by the green stars [147]. 
 
Histone methylation can lead either to gene activation or repression, depending on the 
histone site that is methylated, the degree of methylation (e.g., mono-methylation, di-
methylation, or tri-methylation), amino acid residues affected, and their position in the 
histone tail [211]. Methylation of histones depends on a dynamic process arising from the 
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actions of methyltransferases (HMTs) and demethylases (HDMs) [216]. So far, two 
protein families capable of demethylating lysines are known: the amine oxidases (whose 
major member is protein LSD-1/KDM1A) [217], and jumonji C (JmjC)-domain-
containing proteins (whose first identified member was KDM2A/JHDM1A) [218]. There 
is a reciprocal regulatory effect between the activity of VDR and histone demethylases. 
In the colon cancer cell line SW480-ADH 1,25(OH)2D3 increased expression of lysine-
specific demethylase 1 and 2.  
1,25(OH)2D3 treatment affected also the expression of a series of different JmjC histone 
demethylases, exerting inhibition of expression of KDM4 family members thus 
increasing genome stability, while upregulating members of KDM5 cluster responsible 
for gene repression. In other words, components of the machinery involved in DNA 
epigenetic regulation are primary targets of vitamin D, whose genome transcriptional 
activity can be affected by epigenetic factors.   
In different pathologies, the expression pattern of the nuclear receptor cofactors is altered, 
compromising the effect of 1,25(OH)2D3 [219]. The initial interactions between VDR and 
coactivators are critical for the assembly of intricate multiprotein complexes that remodel 
the chromatin structure, recruit the core transcriptional machinery, and induce expression 
of 1,25(OH)2D3 target genes. Often, differences in responsiveness to 1,25(OH)2D3 depend 
on the expression pattern of the coregulators of VDR [148].  
 
3.3 Epigenetic regulation of the vitamin D system 
The major regulators of 1,25(OH)2D3 levels and signalling CYP2R1, CYP24A1, 
CYP27B1, and VDR, collectively so called “the vitamin D tool” genes, are prone to 
epigenetic regulation. CpG islands span the promoters of CYP2R1, CYP24A1, and VDR, 
while a CpG island is located within the CYP27B1 gene locus (Figure 10). Therefore, 
DNA methylation and histone modifications in these genomic regions can modify the 
chromatin state from an open to closed conformation and lead to transcriptional 
repression of these genes [147].  
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Figure 10. Location of CpG islands in the promoter region of vitamin D tool genes [147]. 
 
Expression of vitamin D system genes resulted deregulated in various types of cancer, 
and these alterations can be partially attributed to epigenetic changes.  
3.3.1 VDR 
Epigenetic corruption of VDR signalling is suggested to be one of the main mechanisms 
that leads to the reduced responsiveness to 1,25(OH)2D3 actions which is frequently 
observed in cancer cells. In fact, in cancer the VDR is not overtly disrupted by either 
genetic mechanisms, such as mutation, or appears to be the subject of cytogenetic re-
arrangements [202].  
Abedin et al. reported that VDR actions in solid tumours are retained, but inhibited by 
epigenetic mechanisms that disfavour selectively antiproliferative target gene promoter 
responses, i.e. through hypermethylation of CpG sites [220]. Furthermore, accumulation 
of VDR-associated corepressors in cancer cells could inappropriately sustain histone 
deacetylation around the VDRE or target gene promoter regions, so that transcriptional 
repression of antiproliferative VDR target genes can occur [220]. Targeting this 
molecular lesion with co-treatments of vitamin D3 compounds plus HDAC inhibitors 
resulted in a more transcriptionally permissive environment to favour expression of 
antiproliferative genes.   
In breast tumours, methylation of exon1a of the VDR gene was reported significantly 
higher (65% of CpGs methylated) compared with normal breast tissue (15% of CpGs 
methylated) [221]. In vitro, in breast cancer cell lines, three hypermethylated regions in 
exon1a became demethylated after treatment with the DNMT1 inhibitor 5-aza-2’-
deoxycytidine (DAC) and VDR mRNA expression increased. These regions were in 
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proximity to the SP1 binding sites (approximately 790 bp from TSS [Transcription Start 
Site]), NFκB binding sites (approximately −480 from TSS), and the exon 1a  TSS. 
Treatment with 1,25(OH)2D3 had no effect on methylation of these regions [221]. To note, 
the same Authors reported an association between VDR promoter methylation and 
expression of 5’ truncated variants of VDR, selectively found in cancer samples.   
In contrast, no methylation of the VDR promoter region was observed in colon cancer 
cell lines, and treatment with the demethylating agent DAC did not increase gene 
expression [222]. 
In parathyroid tumours the expression of VDR is decreased [223];  however, no 
differences in DNA methylation of VDR were observed between parathyroid tumours and 
healthy controls [224]. Similar results were seen in parathyroid adenoma samples, which 
showed decreased expression of VDR, but showed no promoter methylation [225]. 
Epigenetic silencing of VDR has been reported in colorectal cancer metastasis. VDR 
becomes target of polycomb group protein enhancer of zeste homolog 2 (EZH2) which is 
overexpressed in tumours and has histone methyltransferase activity. EZH2 regulates 
H3K27 trimethylation in the VDR promoter, thus resulting in VDR downregulation [226].  
3.3.2 CYP2R1 
CYP2R1 is a microsomal P450 enzyme which hydroxylates both vitamin D2 and D3 at 
position C-25 to form the circulating storage form 25(OH)D3. CYP2R1 promoter region 
is located within a CpG island. Increased CYP2R1 promoter methylation was found in 
leucocyte DNA from subjects with vitamin D deficiency (defined by serum 25-
hydroxyvitamin D [25(OH)D] ≤ 25 nmol/L) [227], but vitamin D supplementation may 
decrease CYP2R1 promoter methylation [228]. 
3.3.3 CYP27B1 
CYP27B1 converts 25(OH)D3 to its active form 1,25(OH)2D3. CYP27B1 gene coding 
sequence contains a CpG island. In breast cancer cells MDA-MB-231, CYP27B1 
hypermethylation leads to gene silencing which can be reversed by treatment with 
deoxyC. Similar results came from studies with non-Hodgkin lymphoma. Combination 
of the DNMT1 inhibitor DAC and the HDAC inhibitor TSA resulted in increased activity 
of CYP27B1 in prostate cancer cell lines [147].   
Interestingly, the promoter region of CYP27B1 contains a negative VDRE (nVDRE), 
located approximately at 500 bp. This region is responsible for 1,25(OH)2D3-dependent 
transrepression, which seems to be achieved through recruitment of both HDACs and 
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DNMTs by VDR/RXR to the promoter region of CYP27B1 [229]. Taken together these 
findings are consistent with the VDR-mediated epigenetic regulation in the CYP27B1 
gene. 
3.3.4 CYP24A1 
CYP24A1 encodes 1,25(OH)2D3 24-hydroxilase, an inner mitochondrial membrane P450 
enzyme which catalyses both 25(OH)D3 and 1,25(OH)2D3. CYP24A1 gene promoter is 
spanned by a wide CpG island that includes responsive elements and SP1 binding sites.  
In several human healthy tissues (kidney, skeletal muscle, blood, brain, skin fibroblast, 
sperm), CYP24A1 is expressed at variable levels and CYP24A1 promoter is not 
methylated, or a it is methylated at low levels [147].  
In prostate cancer cells, CYP24A1 promoter methylation downregulates gene expression 
and in clinical studies progression from benign to malignant lesions was paralleled by 
increasing methylation levels of the CYP24A1 promoter. Demethylating agents showed 
the ability to restore CYP24A1 expression in prostate cell lines [230].   
In colon cancer cell lines, CYP24A1 can be induced by treatment with DAC in a cell line 
specific  manner. This effect did not correlate with the methylation state of the promoter 
and therefore must affect genes upstream of CYP24A1 [222].  
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KEY CONCEPTS AND AIM OF THE STUDY 
 
Besides the classical role in calcium and bone homeostasis, 1𝛼,25-
dihydroxycholecalciferol D3 [1𝛼,25(OH)2D3] (calcitriol), the active metabolite of 
vitamin D, has been recognized to have “non-calcaemic” effects in a variety of cells after 
binding to vitamin D receptor (VDR, NR1I1), a member of the nuclear receptor 
superfamily which includes receptors for steroids, thyroid hormones, and retinoic acid 
[145]. The VDR forms homodimers or heterodimers with the retinoid X receptor (RXR, 
NR2B), to allow specific DNA binding. The binding of 1𝛼,25(OH)2D3 with VDR-RXR 
complex is followed by the attachment of this complex to vitamin D responsive elements, 
which then initiate transcription in the promoter of target genes [146,150]. The effect of 
liganded VDR depends on the epigenetic landscape of target gene [147]. There is 
evidence that 1𝛼,25(OH)2D3 protects against tumour formation by several VDR-mediated 
mechanisms, including regulation of growth arrest, cell differentiation, migration, 
invasion, and apoptosis, making it a candidate agent for cancer regulation 
[164,178,231,232]. A relationship between the vitamin D system and the adrenal 
pathophysiology and growth has been recently highlighted [233].  
Previous findings of the research group I attended during my Ph.D program showed a 
decreased expression of VDR mRNA and protein in a small series of human 
adrenocortical carcinomas (ACCs), suggesting the loss of a protective role of VDR 
against malignant cell growth, as reported for other cancer types [234,235]. An aberrant 
global and gene-specific DNA promoter methylation has been observed in human 
adrenocortical tumours, either benign or malignant, implicating dysregulation of steroid 
biosynthesis and adrenal growth [81-83,236,237]. Downregulation of VDR gene 
expression in adrenocortical carcinomas may result from epigenetic events, that is, 
methylation of cytosine nucleotides in CpG island of VDR promoter. In fact, promoter 
methylation is able to distort the transcription factor binding sites, causing transcriptional 
silencing. In continuity with our previous observations [235], the main aim of my study 
was to analyse methylation of CpG sites in the VDR gene promoter of a different and 
larger series of human adrenocortical tissues, comparing adrenocortical adenomas 
(ACAs) with ACC samples. 
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MATERIALS AND METHODS 
 
Patients and Tissue Samples 
The study was approved by the institutional review board of the University Hospital of 
Padova in accordance with the Declaration of Helsinki guidelines as revised in 1983. 
Informed consent was obtained from all individual participants included in the study. The 
preoperative diagnosis was based on the clinical history, symptoms, signs, endocrine 
evaluation, and imaging examination (e.g., MRI, CT). Archival microdissected paraffin 
embedded slides of the patients were used for histological examinations and molecular 
studies. Diagnosis of adrenal malignancy was performed according to the 
histopathological criteria proposed by Weiss et al. [46] and the modification proposed by 
Aubert et al. [47]. Three normal adrenal cortices from adrenal glands of kidney donors 
were also studied. Histopathological slides were classified by two pathologists 
independently, and no discrepancy existed between them. 
 
VDR Promoter Methylation Analysis 
DNA extraction, bisulfite conversion, and bisulfite sequencing PCR 
Total genomic DNA was extracted from formalin-fixed paraffin embedded (FFPE) 
adrenocortical tissues using QIAamp DNA FFPE Tissue Kit (Qiagen, Milan, Italy). DNA 
samples underwent bisulfite conversion using EZ DNA Methylation-Gold Kit (Zymo 
Research Co., Milan, Italy). Bisulfite treatment produces a chemical conversion of 
unmethylated cytosine to uracil, which is detected as a thymine after PCR. Methylated 
cytosines are protected from chemical conversion (Figure 11).  
 
Figure 11. Steps of bisulfite-sequencing. Bisulfite converts DNA unmethylated cytosine to uracil. 
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Bisulfite-treated DNA was amplified using two sets of bisulfite sequencing primers 
designed by using MethPrimer (http://www.urogene.org/methprimer/index1.html) 
encompassing the region from −693 bp to −65 bp upstream VDR transcription start site. 
Primer sequences are as follows: 
M1F 5′-GGAATTCGGGATTAGGGATTAGGGAAG-3′ 
M1R 5′ -AATACGTCACCCCCACCTAAACTAACCAAAC-3′ 
M2F 5′-GTTAGTCGCTAGGCGTTTTTTAGCGTTTCGC-3′ 
M2R 5′-TATAAAACAAAATTATCGATAATTATAAATA-3′ 
M3F 5′-GTAGAATTACGGTAGGAAGGGTGGGGGGTTG-3′ 
M3R 5′-CCCCGCCCACAAATCCAATCCTCTCTTACC-3′ 
PCR products were separated by electrophoresis and isolated using a Centri-Sep Columns 
(Princeton Separations, Milan, Italy). DNA was sequenced using the Reverse Primer 
(M1R and M2R) with an Applied Biosystems automated fluorescent sequencer (Applied 
Biosystems, Milan, Italy). In DNA sequence, methylated sites were visually counted. 
 
Pyrosequencing reaction and analysis 
PCR amplification of bisulfite converted DNA with specific methylation assay was 
performed using EpiTect PCR kit (Qiagen). Ready-made VDR assays were purchased 
from Qiagen (Qiagen). The primers were located within CpG islands in the promoter 
region of the target gene. Bisulfite treated PCR products were run in 2% agarose gel for 
quality. For pyrosequencing reactions, 15–20 µL of the bisulfite converted amplified 
DNA was added to a total reaction volume of 85 µL containing binding buffer and 
sepharose streptavidin. This reaction mix was agitated for 10 min at room temperature in 
order to facilitate the attachment of the beads to the biotinylated strands. The double 
stranded DNA was separated using the filter pump and this allowed having only single 
stranded (biotinylated) DNA as a template. This was released to the pyromark plate well 
each containing sequencing primer with annealing buffer in a reaction volume of 25 µL. 
The mixture was denatured for 2 min at 80°C and reannealed at room temperature for at 
least 5 min. The plate was put in the PyroMark Q24 machine and run with relevant run 
file. All sequencing primers contained at least one nucleotide (C not followed by G) to 
control for bisulfite conversion efficiency. A methylation standard (0%, 50 and 100% 
methylated) (EpiTect control set, Qiagen, Sweden, AB) and water were used as positive 
and negative controls, respectively. Data analysis was performed using the PyroMark 
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Q24 software (Qiagen, Sweden, AB). The program evaluates the target CpG sites and 
converts pyrograms to numerical values for peak heights and calculates the proportion of 
methylation at each base as a C/T ratio. Tumour methylation status was defined based on 
comparison to the methylation status of the normal reference samples. A difference of 
more than 5% in methylation for a particular assay between adrenal tumour and normal 
references was regarded as significant difference. Pyrosequencing technique was used in 
order to analyse methylation status of VDR promoter in one of the three carcinomas which 
resulted methylated with standard methylation analysis methods. VDR promoter sequence 
analysed was: ATTYGYGATAGGTYGGGAAYGTGGTTAGTYGYGGTTYG. In this 
sequence Y represents a cytosine, in which a methyl group may be added to form 5-
methylcytosine. A sample of normal adrenal was used for control. 
 
RNA Isolation/Quantitative Real-Time PCR (RT-qPCR) 
Total cellular RNA was extracted from FFPE adrenal tissue slide samples using RNeasy 
Universal kit (Qiagen, Gaithersburg, MD) according to the protocol provided by the 
manufacturer. FFPE tissue was deparaffinized and treated with proteinase K, and 
genomic DNA was removed for total RNA extraction. Total RNA was quantified by 
Nano-Drop 1000 Spectrometer (ThermoScientific, Wilmington, DE). Quality of RNA 
was analyzed by Agilent Bioanalyzer 2100 (Agilent Technologies, Palo Alto, CA). 
Evaluation of gene expression was performed by quantitative RT-PCR. Quantitative PCR 
for VDR and the housekeeping HMBS (hydroxymethylbilane synthase) gene primers 
were as follows: 
 5′-GAAGCCTTTGGGTCTGAAGTG-3′ (VDR forward), 
 5′-CCGCCATTGCCTCCATCC-3′ (VDR reverse), 
 5′-GGCAATGCGGCTGCAA-3′ (HMBS forward), 
 5′-GGGTACCCACGCGAATCAC-3′ (HMBS reverse).  
The annealing temperature was 60°C for all genes. PCR was carried out using a DNA 
Engine (Opticon 2 continuous fluorescence detection system, MJ Research, Waltham, 
MA, USA). For each sample, results were normalized with the HMBS rRNA. 
 
 
Western Blot and Densitometric Analysis  
Adrenal tissue slides were deparaffinized using Xylene (Sigma) for 3 × 10 min and 
protein was extracted using Qproteome FFPE Tissue kit (Qiagen, Milan, Italy) and slides 
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were subjected to western blot analyses by 10% Tris-HCl polyacrylamide gel 
electrophoresis (PAGE) (Invitrogen Co., Eugene, OR, USA) in running buffer 
(Tris/Glycine/SDS). Membranes were probed at 4°C overnight with anti-VDR mouse 
polyclonal antibody (1 : 500, VDR-D6, Santa Cruz Biotechnology, Inc., Santa Cruz, CA, 
USA) and mouse 𝛽-actin, Clone AC-15 (1 : 10 000) (Sigma–Aldrich, St. Louis, MO, 
USA). Primary anti-VDR and anti-𝛽-actin antibodies were detected with a secondary goat 
anti-mouse fluorescent antibody (IRDye 800CW, Li-Cor Biosciences, Milan, Italy) (1 : 
15.000). Signal was acquired by Li-Cor Odyssey Clx (Li-Cor Biosciences). 
Quantification of individual protein bands was measured by Li-Cor Image Studio Digits. 
For each sample, results were normalized with the housekeeping protein 𝛽-actin. 
 
 
Immunohistochemistry 
Immunohistochemical analysis for VDR protein expression was performed on 10% 
formalin-fixed and paraffin embedded adrenal tissue slides. Rat monoclonal antibody for 
VDR (9A7γE101.4) was purchased from Calbiochem (Darmstadt, Germany). 
Immunostaining was performed by the streptavidin-biotin amplification method using a 
Histfine Kit (Nichirei Co. Ltd., Tokyo, Japan). Antigen retrieval was performed by 
heating the slides in an autoclave for 5 min in citric acid buffer (2 mM citric acid and 9 
mM trisodium citrate dehydrate, pH 6.0). The dilution of the primary antibodies was 1:50. 
The antigen-antibody complex was visualized with 3,3′-diaminobenzidine solution [1 
mM 3,3′-diaminobenzidine, 50 mM Tris-HCl buffer (pH 7.6), and 0.006% H2O2] and 
counterstained with hematoxylin. Results were scored semiquantitatively based on 
percentage of positive cells and staining intensity. A human breast cancer specimen was 
used as a positive control. Negative controls were incubated with normal mouse 
antiserum instead of the primary antibody, which uniformly demonstrated no reaction.  
 
Statistical Analyses 
For two-sample comparison, differences between means were assessed by Mann-Whitney 
𝑈 test. Relationships between continuous variables were assessed calculating Spearman’s 
rank correlation coefficient. All results are expressed as mean ± SD for continuous 
variables. 𝑃 values <0.05 were taken as statistically significant. Statistical analysis was 
performed using the GraphPad Prism version 6.0 software (GraphPad Software). 
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RESULTS 
 
 
Clinical Characteristics 
Twenty-three patients (12 females, 11 males) who underwent adrenalectomy for sporadic 
adrenocortical tumours between 2006 and 2014 were classified as ACAs (𝑛 = 15) and 
ACCs (𝑛 = 8). The cohort was different from that described in the publication by Pilon et 
al. [235]. Fifteen patients with ACA included 2 cortisol-producing adenomas, 10 
aldosterone-producing adenomas, and 3 non-functioning adenomas: 7 were females and 
8 males, ranging from 31 to 67 years of age (mean age of 51.3 years at presentation). 
Eight ACCs consisted of 5 females and 3 males, ranging from 33 to 73 years of age (mean 
age of 52.7 years). 
 
Clinical and tumour characteristics of the 8 ACC patients, including ENSAT stage at 
surgery [42], are depicted in Table 5.  
 
Table 5. Clinical and tumour characteristics of the ACC patients analysed in the study. 
 
Sample ID Age Gender 
Stage at 
surgery 
(ENSAT) 
Hormonal 
hypersecretion 
Weiss 
score 
Size (cm) Outcome 
C1 58 F III 
Cortisol + 
Androgen 
6 18 
Died for recurrence 4 
years after surgery 
C2 51 M III Cortisol 5 9 Alive, with recurrence 
C3 36 F III Cortisol 9 11 
Died for recurrence 6 
months after surgery 
C4 73 F III 
Non-
functioning 
9 15 
Died for recurrence 1 
year after surgery 
C5 52 M IV 
Non-
functioning 
10 15 
Died for recurrence 2 
years after surgery 
C6 33 M III Cortisol 8 14 Alive, with recurrence 
C7 51 F III 
Non-
functioning 
6 6 Alive, with recurrence 
C8 68 F II Cortisol 9 8 
Died for recurrence 2 
years after surgery 
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Five ACCs patients had endocrine symptoms and signs of excess cortisol secretion; three 
patients had non-functioning adrenal mass. All patients with ACCs were treated with the 
adrenolytic drug mitotane, 1,1-dichloro- 2-(o-chlorophenyl)-2-(p-chlorophenyl) ethane 
(o,p′-DDD), before surgery. Specifically, mitotane was given before surgery to the five 
patients with Cushing’s syndrome because of hypercortisolism not amenable by other 
inhibitors of steroidogenesis; the remaining 3 patients were treated with mitotane as 
adjuvant therapy before second operation for recurrent disease. Mean adrenal tumour 
diameter in ACAs and ACCs group was 14 mm and 120 mm, respectively. Mean post-
surgery follow-up of patients was 72 months (range of 12–120 months) for ACAs and 26 
months (range of 6–48 months) for ACCs. 
 
VDR Promoter Methylation Analysis 
Methylation in the VDR promoter was observed in 3/8 ACCs specimens, which included 
two cortisol-producing and 1 non-functioning carcinoma patients (C3, C4, and C6 
patients in Table 5). Two PCR products, including region from −693 to −65 bp, contained 
42 CpG islands, and 27 of them (64%) were methylated. One representative case is 
presented in Figure 12. Methylation sites were identical in all 3 ACCs tissue specimens. 
No VDR promoter methylation was found in the other 5 ACCs, 3 normal adrenals, and 
the 15 ACAs. 
 
 
Figure 12. VDR methylated sites of VDR promoter region from −693 to −65 bp in one representative 
adrenocortical carcinoma, analysed by bisulfite sequencing. In DNA sequence, bold types indicate all 
CpG dinucleotides, and underlined CpG indicate methylated sites. 
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Pyrosequencing technique was performed in one carcinoma sample from the subgroup of 
the three carcinomas which resulted methylated with standard methods. Pyrosequencing 
provided quantitative evaluation of methylation in the analysed sequence and showed 
significantly higher methylation in two CpG sites (n. 1 and n. 4) of the promoter of VDR 
gene in the carcinoma sample compared to normal adrenal (Figure 13). 
 
 
A] ACC (sample 3) 
 
 
B] Normal Adrenal (N.A.)  
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Position 1* 2 3 4* 5 6 
Quality Passed Passed Passed Passed Passed Passed 
Meth (%) 
ACC  
10 4 6 5 6 3 
Meth (%) 
N.A. 
1 1 6 0 8 5 
 
Figure 13.  Pyrograms of VDR methylation status analysis in the VDR gene promoter of the 
carcinoma sample (A) compared to normal adrenal (B). Methylation percentages are expressed for 
each of the six CpG sites included in the analysed sequence of VDR promoter region. 
     
 
 
 
 
VDR Gene Expression 
VDR RT-qPCR and Immunoblot 
RT-qPCR analysis demonstrated variable levels of VDR mRNA in all adrenal tumours, 
with VDR mRNA expressed at higher levels in ACAs than in ACCs (0.41 ± 0.2 versus 
0.11 ± 0.08 arbitrary units, 𝑃 < 0.01) (Figure 14 A). VDR immunoblot in representative 
cases of a normal adrenal (NA), ACAs, and ACCs is shown in Figure 14 B. VDR/𝛽-actin 
protein levels, measured in the entire series of tumour specimens, showed results similar 
to VDR mRNA in terms of difference between benign and malignant tumours (0.20 ± 0.2 
versus 0.04 ± 0.06 arbitrary units, 𝑃 < 0.05) (Figure 14 B). Low or absent VDR expression 
was observed in individual cases of either ACAs or in ACCs. A positive correlation 
between VDR mRNA and VDR/𝛽-actin levels (𝑃 < 0.003) was observed (Figure 14 C). 
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Figure 14. Expression of VDR in normal human adrenals, in adrenocortical adenomas (ACAs), and 
in adrenocortical carcinomas (ACCs). A) Individual mRNA levels and means (horizontal bars) of  
VDR, measured by qPCR, in normal adrenals (𝑛 = 3), ACAs (𝑛 = 15), and ACCs (𝑛 = 8). B) VDR 
immunoblot (above) in representative cases of a normal adrenal (NA), ACAs, and ACCs, and 
individual VDR/𝛽-actin protein levels (below) in normal adrenals, ACAs, and ACCs. C) Correlation 
between VDR mRNA and VDR protein levels in all tissue samples, including normal and neoplastic 
adrenal. Black dots indicate methylated tissue samples. Mann-Whitney 𝑡-test ACAs versus ACCs. ∗∗ 
𝑃 < 0.01; ∗ 𝑃 < 0.05. Spearman correlation 𝑟𝑠 = 0.56; 𝑃 < 0.003. 
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VDR immunohistochemistry  
Immunohistochemical staining for VDR of representative cases of one normal adrenal, 
one ACA, and one of the 3 methylated ACCs is reported in Figure 15. Both nuclear and 
cytoplasmic VDR immunostaining, consistent with translocation of VDR from cytoplasm 
to the nucleus after ligand binding [235], were observed in the 3 normal adrenals and in 
ACAs. At variance, expression of VDR was undetectable or very weak and limited to 
only scattered tumour cells in all ACCs, including the 3 methylated cases (Figure 15). 
 
 
Figure 15. Immunohistochemical staining of VDR in a normal adrenal (left panel), one ACA (central 
panel), and one methylated ACC (right panel), showing clear VDR expression in NA, in a cortisol-
producing ACA, in both the nucleus and predominantly the cytoplasm, and very weak VDR 
expression, limited to rare cells, in a cortisol-producing ACC. Sections were counterstained with 
hematoxylin. 
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DISCUSSION 
Adrenocortical carcinoma (ACC) is a rare but aggressive malignancy with a very poor 
prognosis [1,59,125]. Complete surgical resection is virtually the sole hope of cure in 
ACC [3]. Recurrence occurs in approximately 60-80% of patients even after so-called 
radical resection, indicating a need for adjuvant treatment [120]. To date, adrenolytic drug 
mitotane, alone or combined with cytotoxic agents, remains the treatment of choice for 
the majority of patients [121]. Despite advances in diagnosis and treatment of ACC over 
the past years, molecular mechanisms underlying ACC development are still not fully 
elucidated.   
Recent observations by Pilon et al. [235] reported a lower mRNA expression levels at 
RT-qPCR as well as weaker immunohistochemical expression of VDR in ACCs 
compared with adenomatous and normal adrenal tissues, suggesting a protective role of 
VDR against malignant adrenocortical cell growth. 
Results of my study, performed in a different series of malignant and benign tumours, 
confirm a reduced expression of VDR in ACC samples, both at transcriptional and 
translational levels. Different molecular mechanisms might cause the reduced or nearly 
absent expression of VDR mRNA and protein observed in ACCs. 
A somatic VDR gene mutation could occur in ACC, reflecting a mechanism implicated 
in the malignant transformation of adrenocortical cells concerning the loss of function of 
a tumour suppressor gene, similarly to what reported for ZNRF3 and p53 [94]. I did not 
analyse this possibility in this study. However, absence of evidence for VDR gene 
mutation in a recent whole-exome sequencing analysis of a very large number of ACCs 
[94] makes unlikely this event. Furthermore, VDR gene is rarely mutated during 
carcinogenesis [202]. Miller et al., looking for alterations in the VDR gene in a variety of 
cancers including 68 osteosarcomas, 23 other sarcomas, 34 non–small cell lung cancers, 
and 44 cell lines representing many tumour types, concluded that deletions, 
rearrangements and point mutations affecting the coding region of the VDR gene play a 
marginal role in the cancers they investigated.  
Epigenetic mechanisms play a crucial role in regulating gene expression [211]. In my 
research, I hypothesized an epigenetic silencing of VDR gene in malignant adrenocortical 
tissues in order to provide an explanation for their low VDR expression. Epigenetic 
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inactivation of human VDR, reducing its mRNA and protein expression, has been shown 
in various cancer types [147,238], supporting the loss of an antiproliferative role of VDR 
[235].  
Disruption of promoter activity by DNA methylation of CpG sites is a well-known 
epigenetic mechanism aimed at inactivating gene expression, an event which frequently 
affects tumour suppressor genes in cancer [211]. In general, cancer cells exhibit a global 
DNA hypomethylation with hypermethylation of tumour suppressor gene promoters 
[204]. Notably, the promoter of VDR gene lies in a CpG-rich island and contains strong 
regulatory sequences relevant for its transcriptional activity [239]. All these premises 
make VDR gene promoter methylation potentially involved in ACC.  
Results from bisulfite sequencing performed with standard methods support a VDR gene 
silencing through this epigenetic mechanism in a subgroup of ACCs. Along with these 
results, pyrosequencing analysis, which is the most sensitive and accurate method to 
detect methylation at a single CpG [240], confirms an increase of methylated CpG in the 
ACC sample compared to the normal adrenal. Although pyrosequencing has not been 
performed in all tissue specimens, this result makes us more confident of the reliability 
of standard bisulfite sequencing. Whether methylation of VDR promoter is the mainly 
contributor of the reduced VDR expression in the three (hyper)methylated ACCs of entire 
series remains undemonstrated. Likewise, the contribution of VDR epigenetic silencing 
to the development of adrenal cancer requires further investigations. In fact, previous 
experimental studies using the H295R adrenocortical carcinoma cell line as a model 
corroborated that VDR is a key effector for proliferation in this human ACC cell line 
[235]. Nevertheless, the fact that the methylated CpG sites resulted the same in all the 
three methylated ACCs raises questions about the potential relevance of these specific 
sites with regard to the VDR promoter activity.  
Different epigenetic mechanisms explaining the downregulation of VDR gene expression 
can be hypothesized for the remaining ACCs, and possibly for some of the adenoma cases 
with low VDR expression.  
VDR corruption could be caused by a dysregulation of chromatin environment. In 
addition to aberrant DNA methylation in CpG islands, disruption of normal patterns of 
covalent histone modifications is another hallmark of cancer. One of the most character-
istic example is the global reduction of the histone trimethylation of H4K20 (H4K20me3) 
and acetylation of H4K16 (H4K16Ac), along with DNA hypomethylation, at repeat 
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sequences in many primary tumours [204]. Furthermore, there are many examples of 
alterations in enzymes that add, remove or recognize specific modifications in specific 
types of cancer. Overexpression of individual histone deacetylases (HDACs), such as 
HDAC1, HDAC2 and HDAC6, among others, has frequently been recognised in tumours 
[241]. Despite growing evidence regarding the involvement of histone modification 
pattern in tumorigenesis, to date scarce data are available for adrenal cortex tumours. 
Recently, Davis et al. [242] reported that the oncogenic potential of two epigenetically 
distinct SW13 subtypes could be changed after treatment with HDAC inhibitors, 
involving different expression of two tumour suppressor genes. These findings are 
consistent with the hypothesis that chromatin remodelling and modulation can be 
involved in the epigenetic mechanisms underlying adrenocortical tumour growth and 
spread.   
Insights into the complex network of chromatin remodellers involved in VDR gene 
control come from studies in colorectal cancer cell lines, suggesting that deregulation of 
the HDAC system [243], or EZH2-mediated trimethylation of H3K27 [147,226] in the 
VDR promoter can affect VDR expression. We cannot exclude that similar dysfunctions 
in these enzymes causing VDR downregulation could occur also in ACCs.  Whether these 
alterations are present in the adrenocortical tumours examined in my study has not been 
investigated.   
Unbalance of VDR corepressors in ACC cells could be an alternative mechanism 
concerning the reduced VDR expression. As known, these molecules can interact with a 
lot of nuclear regulatory cofactor complexes, therefore affecting nuclear hormone 
receptor binding to DNA responsive elements, therefore leading to gene functional 
inactivation [147]. To date, data about altered expression of VDR corepressors in adrenal 
cancer are however not available.       
There is evidence that deregulation of short noncoding RNAs (miRNAs) could occur in 
adrenocortical tumours [244,245]. Additionally, a number of miRNAs may repress VDR 
post-transcriptionally in cancer [246]. Two miRNAs – miR-125b and miR-27b - 
regulating the amount of VDR were found, but both miRNAs can reduce VDR on the 
protein level with no effect on the mRNA level, indicating blockage of translation rather 
than increased mRNA degradation [247]. This is in contrast with the results obtained from 
VDR expression analysis in our series of ACCs, which showed VDR decreased at both 
mRNA and protein levels. Furthermore, miR-125b has been reported downregulated in 
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adrenocortical tumours [87,245], as mentioned for other cancers [246]. Taken together, 
these observations make unconvincing the role of these two miRNAs to explain the 
reduced VDR expression in our ACCs. However, other miRNAs might act as specific 
VDR downregulators in adrenocortical tumours although this has not been proven yet.  
Since a growing body of evidence indicates that DNA promoter methylation can be a 
consequence rather than a cause of transcriptional inactivation, the hypothesis of VDR 
methylation as the result of malignant transformation cannot be definitely excluded. To 
note, methylation of VDR gene promoter has not been specifically reported in all genome-
wide methylation studies on adrenocortical cancer [81-83]. As global methylation pattern 
of the ACCs included in my study is not known, it is difficult to establish if VDR 
epigenetic inactivation could have to some extent a causal role with regard to ACC 
development rather than being an epiphenomenon of a genome-wide hypermethylation.  
Moreover, I cannot exclude that low expression of VDR gene in adrenocortical cancers, 
as well as in some adenomas, may rather be due to the effect of hormonal compounds, 
that is, estrogens, thyroid hormone, and glucocorticoids, which are likewise able to alter 
VDR mRNA/protein levels [146]. Interestingly, a critical role of estrogens and ER𝛼 in 
adrenocortical tumorigenesis has been reported [104].  
Finally, mitotane, the drug used for preoperative treatment of all ACC patients enrolled 
the study, is known to stimulate CYP3A4 expression, potentially leading to reduced 
1𝛼,25(OH)2D3 bioavailability and thus influencing VDR regulation in adrenal cortex cells 
[235,248]. Furthermore, knowledge is lacking about the effect of mitotane per se on VDR 
expression in adrenocortical cancer cells [126], besides the potential effects exerted by 
glucocorticoid levels perturbation.  
The main limitation of the study is the relatively small number of samples, and a larger 
ACCs study population is needed to confirm these results. The study could be enlarged 
using the adrenal tissue bank of ENSAT (European Network on Adrenal Tumors) 
collaborative group, which is dedicated to the study and treatment of adrenal tumours, 
providing study projects and enrolling research teams on this disease.  
Notwithstanding, the results of my Ph.D research project represent the first evidence of 
an association between VDR gene promoter methylation and reduced VDR expression in 
ACC. This suggests a potential role of VDR epigenetic inactivation in malignant 
adrenocortical tumorigenesis. Adrenocortical carcinoma, either silent or hormonally 
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active, is a rare tumour with a dismal prognosis because of its highly invasive phenotype 
and marked resistance to radio- and chemotherapy [3,120]. The VDR promoter 
methylation might become a target for pharmacological agents to treat adrenal cancer in 
selected cases [100], i.e. ACC with differently methylated VDR promoter. In this regard, 
the human adrenocortical carcinoma H295R cell line, which provides the most 
appropriate model for ACC study [249], does not have VDR gene methylation (personal 
observation). The availability of adrenal cell models allowing the in vitro use of DNA 
methylation inhibitors should be addressed. 
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